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South Africa has one of the highest prevalences of drug misuse and abuse in Africa. Salt River 
Mortuary (Cape Town, South Africa), along with other national Forensic Pathology Service 
providers, receives many cases of suspected drug-related deaths. In some cases, the traditional 
autopsy – when viewed together with the decedent's history – is not able to indicate whether a 
drug-related death is accidental or suicidal in relation to altered drug metabolism. Literature 
has shown that this can be investigated by sequencing gene(s) encoding the implicated 
metabolising enzyme(s) in a postmortem genetic analysis. However, as such an analysis would 
normally be performed following the obtainment of postmortem toxicological results, it is 
imperative to investigate whether blood samples retrieved back from a toxicology laboratory 
would be sufficient for the said genetic analysis, despite the handling involved in the process 
of toxicological investigation. To this end, blood samples from 30 deceased individuals in 
which drug use/abuse may have contributed to death, were collected into two red-top tubes 
(plain), two grey-top tubes (containing sodium fluoride and potassium oxalate) and one EDTA-
containing purple-top tube (control). DNA was immediately extracted from one of each colour 
tube, while the duplicate red-top and grey-top tubes first underwent a process of toxicological 
analyses, and then underwent DNA extraction. The concentration, degradation, purity, 
contamination, and quality of DNA were assessed using real-time PCR, spectrophotometry, 
forensic DNA profiling, and Sanger sequencing. In contrast to the grey-top tubes, the results 
showed that the red-top tubes were most suitable for the aforementioned genetic analysis. 
Overall, the study not only demonstrated that postmortem genetic analysis using samples 
retrieved from a toxicology laboratory is possible in the local context, but also provided 
guidelines around the pre-analytical phase of the analysis. These results illustrate the 
opportunity to investigate these toxicogenetic avenues further, particularly in future expansion 
of services currently provided at Salt River Mortuary, which may provide families more 










Forensic toxicology is a branch of forensic science that studies the adverse effects caused by 
drugs and chemicals in humans (Lappas and Lappas, 2016). The need for the complete 
establishment of the field of forensic toxicology in South Africa is reinforced by the high rate 
of drug use seen in the country. Otu (2011) described South Africa and Nigeria as being “in a 
class of their own” when it comes to the prevalence of drug use (Otu, 2011). Of all the sub-
Saharan African countries, South Africa is considered to have the largest market for illicit drugs 
(Peltzer et al., 2010). This has been ascribed to many factors, including the movement of large 
numbers of people across the South African borders (legally and illegally), an increase in the 
number of international flights into the country since 1994, visa requirements that are relaxed 
for South Africans travelling across the borders, as well as customs and borders that are not 
patrolled properly (Peltzer et al., 2010). The prevalence of drug use in South Africa is also 
suspected to be related to the affluence of the country relative to other African countries, which 
is seen to facilitate the creation of urban centres, the lifestyles of which are characterised by 
the rife use of drugs (Peltzer et al., 2010). 
 
The argument about urbanised areas being most affected the most by the rampant use of drugs 
is supported by the statistics of drug misuse reported within the borders of South Africa. 
According to data produced by the South African Community Epidemiology Network on Drug 
Use (SACENDU) for the year 2017, the province of the Western Cape has the second highest 
prevalence of drug use, after the Gauteng province (SACENDU, 2017); the two provinces in 
which the biggest cities in the country are found. 
 
The South African government has passed laws aimed at reducing the demand and supply of 
drugs, including the Drugs and Drug Trafficking Act No. 140 of 1992 and the Prevention and 
Treatment for Substance Abuse Act No. 70 of 2008 (Pienaar and Savic, 2016). However, the 
Western Cape-based Salt River Mortuary (along with other mortuaries in the country) still 
receives cases of drug-related death. There is, however, a possibility that some of those cases 
do not involve the abuse of the detected drugs, as studies have shown that some people are 






doses that are normally not associated with toxicity (Zanger and Schwab, 2013). One way in 
which such deaths could be further investigated is through a genetic analysis aimed at assessing 
the sequence of the genes encoding the enzymes that catalyse the biotransformation of the 
implicated drugs; a service currently not offered by the South African forensic government 
services. One such group of enzymes is the cytochrome P450 enzyme family, for which an 
overview is provided below. This chapter also reviews the literature available on the pre-
analytical processing that requires consideration before the implementation of the said genetic 
analysis. Finally, the literature review assesses the storage of blood specimens in blood 
collection tubes intended for toxicological analysis, within toxicological environments, and 
prior to the performance of the aforementioned genetic analysis – which is the focus of this 
study. 
 
1.2. Cytochrome P450 enzyme family 
 
1.2.1. Introduction to Cytochrome P450 
 
The metabolic systems of the human body carry out various chemical reactions to sustain life, 
including responding to internal stimuli, deriving and processing nutrients from ingested foods, 
and adequately responding to xenobiotic substances such as drugs and toxic compounds 
introduced into the body by a variety of mechanisms (Motulsky, 1957). Cytochrome P450 
(CYP) is a superfamily of enzymes that catalyses 90% of phase I of metabolic processes (Arici 
and Ozhan, 2017), which occur largely in the liver (Zanger and Schwab, 2013). Phase I 
enzymes alter substrates using reactions such as oxidation, hydrolysis, reduction, alkylation, 
and dealkylation, while phase II reactions include conjugation of products of phase I reactions 
with glucuronic acid, glycine, acetate, and sulphate to promote elimination (Sono et al., 1996).  
 
CYP P450 enzymes are so called because they are hemoproteins (represented by 
“cytochrome”) and their spectral property allows them to absorb pigment (“P”) or light at a 
wavelength of 450 nanometers (Jaiswal et al., 1985). All members of the CYP group are called 
monooxygenases due to their mechanism of action (Bernhardt, 2006). This involves the 
incorporation of a molecular oxygen into the substrate while simultaneously reducing the 
second molecular oxygen of the disintegrated dioxygen molecule with two hydrogen atoms to 






structure, which reflects their genetic makeup, and forms the basis by which they are 
differentiated (Nelson, 2004). 
 
In humans, there are 57 putatively functional genes (Nelson, 2018) and 58 pseudogenes 
encoding CYP enzymes, which are grouped into 18 families and 44 subfamilies according to 
their sequence similarities (Nelson, 2004). Most of the genes encoding CYP enzymes code for 
constitutive enzymes that facilitate endogenous non-metabolic processes. Only a few CYP 
enzymes, belonging to the CYP families 1, 2 and 3, catalyse the oxidative biotransformation 
of xenobiotic compounds (such as drugs) that are of particular relevance to the topic at hand 
(Nebert and Russell, 2002).  
 
1.2.2. Family CYP 2 
 
The CYP 2 family consists of 16 full-length genes that encode several hepatic enzymes that 
catalyse some of the most important drug-metabolising reactions in humans (Guengerich and 
Cheng, 2011). One such member of this family is CYP2D6 (Nebert and Russell, 2002), which 
will henceforth be the focus of the discussion in this text. 
 
The CYP2D6 enzyme uses hydroxylation and demethylation to metabolise more than 25% of 
clinically important drugs, including antidepressants, antipsychotics, analgesics, antitussives, 
b-blocking agents, antiarrhythmics, and antiemetics (Gopisankar, 2017). Moreover, the 
enzyme plays a pivotal role in the metabolism of methamphetamine (Lin, 1997) – the primary 
drug of abuse in the Western Cape (where the current study took place) (SACENDU, 2017). 
There has not been a full characterisation of all the allelic variants of CYP2D6 (over 
approximately one hundred); however, it is known that haplotypes (alleles with a set of linked 
single nucleotide polymorphisms (SNPs)) such as CYP2D6*1, CYP2D6*2 and CYP2D6*35 
cause a normal or increased enzyme activity, while CYP2D6*9, CYP2D6*10, CYP2D6*17, 
CYP2D6*29, and CYP2D6*41 encode enzymes with decreased activity, and CYP2D6*3, 
CYP2D6*4, CYP2D6*5, and CYP2D6*6 translate to enzymes with no enzyme activity 
(Sakuyama et al., 2008). 
 
While monogenic variability can be used to explain some of the pharmacokinetic and 






influence the manner in which different individuals react to drugs, including non-genetic host 
factors (Zhang et al., 2011) and epigenetic factors (Zanger and Schwab, 2013). The focus of 
this study is, however, on the genetic factors. 
 
1.2.3. Genetic influence on CYP activity 
 
The metabolic phenotypes of many allelic variants of the CYP genes were studied and 
described to form the foundation of pharmacogenetics – a branch of pharmacology concerned 
with the influence of genetic factors in drug response (Gandhi et al., 2004). Four phenotypic 
classes were inferred from the genotypic data of these genes and described by Benet et al. 
(1996) as follows: (1) poor metabolisers (PM) carry enzymes that are encoded by homozygous 
alleles that have a complete lack of function; (2) intermediate metabolisers (IM) carry one allele 
with a complete lack of function and one allele with a normal function, or homozygous alleles 
that have a reduced function; (3) extensive metabolisers (EM) carry homozygous alleles with 
normal function (this is referred to as the “normal phenotype” and represents the majority of 
the population); and (4) ultrarapid metabolisers (UM) have a mutation that increases enzyme 
activity (this is usually the duplication of the “normal” gene). 
 
Zanger and Schwab (2013) remarked that the pharmacological impact of these different allelic 
variants is pronounced with PM and UM phenotypes, by reporting that when a 
pharmacologically active compound was in the blood, it would remain longer in PM 
individuals due to reduced or no clearance, resulting in inadvertent drug toxicity, while there 
was a rapid clearance in UM individuals, resulting in the loss of the pharmacological effect of 
the drug (Zanger and Schwab, 2013). The converse is true for a prodrug. This unintended 
response to a drug at a conventional dose – called an adverse drug reaction (ADR) – sometimes 
contributes to sudden unexpected death (SUD), thus entering the purview of forensic 
investigations. The term ‘forensic toxicogenetics’ has been coined for the interdisciplinary use 
of toxicological and genetic investigations in these cases (Sajantila et al., 2010). 
 
1.3. Forensic toxicogenetics 
 
In some SUD cases the cause of death is reported as “undetermined” after the performance of 






ancillary investigations, such as histology and toxicology are also negative in relation to the 
determination of the cause death. This has led to the emergence of the concept of molecular 
autopsies – an expansion of the traditional autopsy to include a genetic examination of the 
deceased (McElroy et al., 2000). Forensic toxicogenetics, as a form of molecular autopsy, is 
relevant in the local context, given that the fatality rate due to ADRs in South Africa was 
estimated to be five to ten times higher than the prevalence observed internationally (Warnich 
et al., 2011).  
 
Academics and practitioners in the field of forensic pathology hold different views on the need 
for toxicogenetic investigation in postmortem cases. Most of what is empirically known about 
forensic toxicogenetics is from case reports that involved a single drug, including oxycodone 
(Jannetto et al., 2002), tramadol (Levo et al., 2003), citalopram (Holmgren et al., 2004), and 
amitriptyline (Koski et al., 2006). The general finding from these studies was that the 
polymorphic nature of the CYP enzyme-encoding genes did not have a significant impact on 
the toxicity of the aforementioned drugs. A review published by Sajantila et al. (2010), 
however, demonstrated how postmortem genetic analyses may provide important insight into 
the cause and/or manner of death by citing a number of drug-related death cases. This included 
a toxicity fatality resulting from administration of prescribed fluoxetine medication in a 9-year-
old boy (Sallee et al., 2000) and morphine intoxication in a neonate breastfed by a mother 
taking codeine medication (Koren et al., 2006). Both of these cases involved reported ADRs 
that implicate the different metabolic capacities exhibited by different polymorphisms of genes 
encoding CYP enzymes. Sajantila et al. (2010) did concede, however, that further research is 
still required before forensic toxicogenetic analysis can be integrated into standard forensic 
practice (Sajantila et al., 2010). 
 
It may be suggested that in the routine forensic setting, the performance of a toxicogenetic 
analysis would be as a response to an observation of inexplicable toxicological results; that is, 
when parent and metabolite concentrations observed in the blood (and/or other specimens) of 
the deceased are inconsistent with medical/circumstantial history, which would warrant a 
genetic analysis to try and make sense of the observed discrepancy. It is, therefore, important 
– when designing a strategy on how the test would be applied routinely in situations such as 






investigations that may affect the ability to perform a subsequent genetic analysis using the 
same samples. 
 




The factors that commonly lead to variations in analytical results can either be in vivo or in 
vitro (Wisser et al., 2002). Although it is important for analysts to be cognisant of all of these 
factors, there is little one can do to prevent the contribution of the in vivo influences in the 
variation of analytical results, particularly in postmortem cases where the postmortem interval 
(PMI) is uncontrolled and usually unknown (Guder, 1999). However, in vitro interferences – 
which include components of sample composition, storage, and processing (Skopp, 2004) – 
may be controlled, and it is around them that an effective analytical strategy must be devised 
in order to limit/prevent drug concentration alterations. 
 
Postmortem investigations are, by nature, interdisciplinary. The different forms of training the 
officers involved (including forensic pathologists, forensic pathology officers, police officers, 
and toxicologists) receive means that there is no guarantee that the guidelines provided on how 
to collect different sample types will always be followed. Another way in which the 
interdisciplinary nature of postmortem investigations manifests its significance in pre-
analytical processes is in the selection of an appropriate sample – an exercise that forms part 
of a broader group of factors in the pre-analytical process collectively known as sample 
handling (Kerrigan, 2013).  
 
1.4.2. Sample handling in the context of forensic toxicology 
 
1.4.2.1. Specimen selection: significance of blood in postmortem toxicology 
 
Over the years in the field of forensic toxicology, and particularly postmortem toxicology, 
research has been conducted to identify the biological specimens that are best suited and 
informative for general and specific drug and chemical analysis (Kerrigan, 2013). As such, the 






case and the purpose for the toxicological analysis (Drummer, 2004). Blood is collected more 
frequently than other biological specimens because of the added benefits it offers over other 
specimens (Kerrigan, 2013). Urine, vitreous humour, and gastric contents are also collected by 
forensic pathologists in most drug-death cases. Most alternative specimens such as liver, brain, 
muscle, fat, and bone tissue, are usually used for more specialised testing (Kerrigan, 2013). 
 
Blood is the most commonly used specimen for analytical purposes in forensic toxicology, 
particularly in postmortem toxicology, as analytical results are usually utilised to distinguish 
whether a drug may have contributed to intoxication (Kerrigan, 2013). This can be attributed 
to the vast amount of research that has focused on blood for this purpose of interpretation in 
ante- and post-mortem specimens (Wille et al., 2009).  However, although postmortem blood 
is usually available for toxicological analysis, there is variability in drug concentration between 
different blood collection sites (Dalpe-Scott,1995; Zilga et al., 2017), which explains why it is 
important to note the exact site from which blood is collected.  
 
The two main types of blood that may be collected at autopsy internationally are central blood 
(taken from the right chamber of the heart) and peripheral blood (taken from areas distant to 
the torso region, the most common ones being femoral and iliac) (Kerrigan, 2013). Forensic 
pathologists are discouraged from taking central blood, as it is considered to be non-
homogeneous (Jones, 2007) and more susceptible to contamination and postmortem 
redistribution (PMR) (Yarema and Becker, 2005). While central blood may be suitable for 
screening purposes, peripheral blood is recommended for quantitative analysis, as it is 
suggested that PMR is less so in femoral blood (Kerrigan, 2013). However, this doesn’t negate 
the possibility of distribution in femoral sites between death and autopsy (Gerostamoulos, 
2012). Regardless of the site of blood collection, the requirements for proper storage are the 
same. 
 
1.4.2.2. Specimen storage 
 
Pharmacokinetics involves introduction of xenobiotic compounds into the body, which are 
acted upon by the body’s physiological mechanisms – changing the compound’s 
physicochemical properties in the process – in an effort to remove the foreign material from 






hydrolytic derivatives takes place even after death in processes that can happen both in situ and 
in vitro (Drummer, 2004). Several studies have shown how the putrefactive processes that take 
place after death could significantly alter the concentration of drugs in the body. For instance, 
Moriya and Hashimoto (2003) demonstrated how anaerobic bacteria – which play a central role 
in the process of decomposition – may be responsible for the observed conversion of 
nitrobenzodiazepines such as flunitrazepam, nitrazepam, clonazepam, and nimetazepam, to 
their respective 7-amino-metabolites (Moriya and Hashimoto, 2003). Minimising microbial 
activity in the body of the deceased, which can be achieved by creating conditions under which 
microbial growth is unfavoured, has been recommended. Mortuaries employ low temperature-
controlled conditions to limit the putrefactive process and hinder microbial activity. Additives 
may also be used in vitro to hinder this activity, as discussed later on.  
 
When a sample of interest has been isolated from the body of the deceased, this preservative 
measure can be maximised by subjecting the isolated specimen to temperatures (among other 
preventative measures) certified to best limit the decomposition of the compound of interest. 
For instance, El Mahjoub and Staub (2000) found that benzodiazepines in whole blood samples 
are stable when stored at –20˚C, demonstrating the importance of temperature control in the 
pre-analytical process of toxicological analysis (El Mahjoub and Staub, 2000). Interestingly, 
the close relatives of benzodiazepines, 7-amino-benzodiazepines, are considerably unstable at 
this temperature; stability for this group of drugs when contained in postmortem blood, is 
reportedly achieved when the matrix is stored at –60˚C (Robertson and Drummer, 1998). This 
suggests that there is no universal temperature under which all drugs in a biological matrix 
remain stable for a specific amount of time, largely due to varying physicochemical properties. 
Stability of drugs in biological matrices in varying containers and at different temperatures are 
therefore aspects that should be evaluated by the toxicology laboratory. 
 
The evaluation of the suitable temperature for the stability of drugs is, however, of limited 
importance when considered in isolation; this piece of information can best be utilised in 
combination with knowledge on the other requirements for the stability of the drug of interest. 
For example, although designer drugs MDA, MDMA and MDEA are all stable at –20˚C, this 
state is maintained for a short period in whole blood when compared to other matrices such as 
serum and urine (Clauwaert et al., 2001), which highlights the relevance of sample selection 







The importance of insight into the various factors that influence the stability of drugs in 
postmortem matrices was also demonstrated in a study by Rees et al. (2012), wherein the 
stability of 6-acetylmorphine (a unique heroin metabolite) in different matrices (blood, vitreous 
humour, and homogenised skeletal muscle) stored with and without a preservative (sodium 
fluoride) at different temperatures (4˚C and –18˚C), was studied over a period of 84 days. While 
the compound was more stable – in all matrices – when the temperature was set at –18˚C, the 
paramount finding of the study was that regardless of the matrix used and the temperature under 
which the specimens were stored, the presence of sodium fluoride substantially increased the 
stability of 6-acetylmorphine, which the authors attributed to the preservative’s ability to inhibit 
the activity of microorganisms in a biological specimen (Rees et al., 2012).  
 
The preservative power of sodium fluoride was also demonstrated by Fjeld et al. (2012), who 
performed reanalysis on specimens that were stored at –20˚C for a period of up to 7.2 years 
and found that the stability of the tested drug (gamma-hydroxybutyrate) had not been affected 
to a significant degree (Fjeld et al., 2012). One of the most common uses of sodium fluoride 
as a preservative is in the storage of biological specimens for ethanol analyses. It has been 
shown that microorganisms such as Candida albicans and Escherichia coli are able to produce 
ethanol from glucose (Quintas et al., 2017), which may mislead toxicologists in the 
interpretation of analytical results. This process has also been shown to be preventable with the 
addition of sodium fluoride in the specimen of interest, which inhibits the activity of the 
ethanol-producing microorganisms (Yajima et al., 2006). 
 
The use of sodium fluoride highlights the use of additives as preservatives of drugs in the 
biological matrix. However, toxicologists also use sample vials with additives intended to 
preserve the natural state of the matrix, and in turn the drugs of interest as well. This is 
especially important for complex biological specimens such as blood, the cellular content of 
which makes it susceptible to postmortem changes. This may be due to the enzymatic, 
hydrolytic, and oxidative activities that take place as a result of microbial invasion and/or 
proliferation, as well as the release of endogenous enzymes in the process of necrosis or 
apoptosis (Alaeddini et al., 2010). An anti-coagulant is used in this case to prevent coagulation 
and degradation of blood cells. Examples of anticoagulant additives include  






these is important in many fields where prevention of blood coagulation is of importance to the 
scientific analysis to be performed. This includes genetics, where blood is often used as the 
source of DNA. 
 
1.4.3. Sample handling in the context of genetics 
 
1.4.3.1. Effects of anticoagulants on DNA 
 
The Division of Forensic Medicine and Toxicology in the University of Cape Town consists 
of a branch that offers forensic pathology investigation services under the Western Cape 
Provincial Government’s Forensic Pathology Service and a scientific branch called Biomedical 
Forensic Science, whose focus is academic research and development aimed at improving the 
manner in which forensic services are rendered to the West Metropole of Cape Town. One of 
the components of the latter branch is Molecular Forensics – the unit under which genetics-
based forensic research falls. When using blood as a biological sample for genetic analysis, 
geneticists make use of EDTA to prevent the coagulation of blood and to render it viable for 
the extraction of high quality DNA on which subsequent molecular analyses are based. This is 
in the form of blood collection tubes with a purple lid (this project made use of 4 mL vials 
supplied by BD Vacutainer (New Jersey, USA) containing 7.2 mg of K2EDTA) – referred to 
here as Purple-top tubes.  
 
The efficacy of EDTA in preventing coagulation without adversely affecting the quality and 
quantity of the DNA in blood was demonstrated by Färne et al. (1999). In the study, EDTA 
was compared to other anticoagulants (including citrate and heparin) and was found to be 
comparable to citrate in its effect on the detectability of DNA by polymerase chain reaction 
(PCR) after the treatment of blood with the tested additives (Färne et al., 1999). Heparin was, 
on the other hand, found to inhibit PCR – an effect that the investigators were able to reverse 
by adding heparinase I in the heparin-treated blood (Färne et al., 1999). This demonstrated an 
important aspect of the treatment of biological specimens, and how this must suit the context 
of the intended investigation. While heparin was successfully used to prevent the coagulation 
of blood, it was rejected as a suitable additive on the basis that it did not allow the investigators 







The study conducted by Färne et al. (1999) confirmed an observation made by Holodniy et al. 
(1991), who determined the effect of a number of anticoagulants (including acid citrate 
dextrose, sodium EDTA, potassium oxalate, and sodium heparin) on the application of PCR 
on the DNA extracted from whole blood, plasma, and separated mononuclear cells that were 
stored in the presence of the aforementioned anticoagulants (Holodniy et al., 1991). The 
researchers found that for all the tested biological specimens the signal obtained from the 
enzyme-linked affinity assay (used to quantify the PCR products) was significantly attenuated 
for all the samples that were stored with sodium heparin, illustrating the inhibition of the PCR 
process – a phenomenon that they, too, were able to remedy by adding heparinase to the 
samples stored with sodium heparin (Holodniy et al., 1991). The inhibitory effect of heparin in 
PCR reactions was again proven in a recent study wherein heparinase was used to negate the 
inhibition of the amplification of microRNA (Li et al., 2016). 
 
1.4.3.2. Effects of preservatives on DNA 
 
This text has explored the role of EDTA as an anticoagulant and the importance of this function 
in the downstream processing of blood and its contents (DNA). However, Lahiri and Schnabel 
(1993) showed that the role of EDTA, as far as blood and DNA are concerned, does not end 
with its anticoagulative effect. In the said study, magnesium chloride (MgCl2) – which was 
required in a procedural step they employed to extract DNA from blood, termed the modified 
rapid method (RM) procedure – was found to have a degradative effect on the extracted DNA 
(Lahiri and Schnabel, 1993). Upon making this observation, EDTA was introduced into the 
vials in which DNA extraction was performed and successfully inhibited the effect of MgCl2, 
thus effectively preserving DNA through direct interaction with components of the blood 
mixture (Lahiri and Schnabel, 1993). This provides an uncommon dimension in the use of 
EDTA as an additive in storage, where a compound reputable for its anticoagulative properties 
is employed for preservative purposes. 
 
The successful use of EDTA in this manner can be attributed to the acid’s ability to form 
chelates with metal ions, which are often required as cofactors for enzymes (including 
endogenous and exogenous nucleases). The chelation of these metal ions by EDTA makes 
them unavailable to the enzymes that require them for their function and thus protecting the 






shown by Huang et al. (1997) that Mg2+ is required for the production of high molecular weight 
fragments of DNA, whereas the production of oligonucleosomal fragments requires the 
presence of the two divalent cations: Mg2+ and Ca2+ (Nakamura et al., 1981; Sun and Cohen, 
1994).  
 
The ability of sodium fluoride to prevent the decomposition of most drugs in a blood matrix 
was discussed above. However, to the author’s knowledge, there are no reports in the literature 
on what effect this additive has on DNA in postmortem blood. It is widely accepted that 
excessive exposure to fluoride causes a condition called fluorosis (Vani and Reddy, 2000). This 
phenomenon could be explained by studies that have shown that fluoride intoxication can 
render cells energy-deficient by altering mitochondrial functions through the inhibition of 
protein synthesis and nucleotide damage (Jeng et al., 1998).  
 
The mechanism by which the fluoride ion exerts its destructive effect on DNA is still elusive; 
however, some explanations have been propounded. Some scientists have suggested that 
fluoride ion binds specifically with certain riboswitch molecules, which undergo a 
conformational change upon the addition of a fluoride ion, contributing to the loss of their 
stability (Ren et al., 2012). Using B-form DNA to investigate the effect of fluoride, Liu et al. 
(2017) also demonstrated that the negatively charged ion affects the stability of DNA hairpin 
(Liu et al., 2017).  
 
The physiological effect of sodium fluoride on DNA was shown whereby a group of mice was 
administered sodium fluoride for a period of 30 days while two control groups were given 
water and black tea (whose anti-oxidative function is known to prevent the destructive effect 
of sodium fluoride) (Anamika et al., 2012). The livers of the mice administered with sodium 
fluoride yielded a significantly low amount of DNA when compared to the control groups 
(Anamika et al., 2012). It should, however, be noted that this was an in vivo-based study in that 
the sodium fluoride was introduced into living organisms and exerted its effect on living cells. 
 
The effect of sodium fluoride in an in vitro setting was investigated by Zhanga et al. (2008), 
who tested the fluoride-induced damage of DNA on isolated primary rat hippocampal neurons. 
In addition to the up-regulation of nuclear factor kappa-light-chain-enhancer of activated B 






the neurons with sodium fluoride significantly damaged the DNA (Zhanga et al., 2008). One 
may argue, however, that the morphology of neural cells may prevent us from using the 
findings of this study to extrapolate on the effect of sodium fluoride on the DNA in a blood 
matrix. This concern was addressed by a study conducted by Podder et al. (2015) in which 
human blood from healthy adult individuals was used to demonstrate that sodium fluoride was 
responsible for the observed DNA fragmentation and could be associated with the induction of 
apoptotic processes in the U87 and K562 cells (Podder et al., 2015).  
 
One notes, however, that none of the cited studies used postmortem blood in their experiments, 
which has properties that are markedly different to those of antemortem blood, as is seen in the 
discrepancies in the levels of ATP, some purines and pyrimidines, and myoglobin (El-Seshley 
et al., 1999). The fragmentation of DNA (in postmortem blood) as a result of the action of 
internal nucleases that are released from cells shortly after death as part of an apoptotic or 
necrotic process, is another marked difference (Johnson and Ferris, 2002; Nazir et al., 2011). 
 
1.5. Knowledge gap and motivation 
 
While there is evidence to show that toxicogenetic investigations can assist with the 
determination of the cause and/or manner of death, there has been limited research under this 
topic in a South African context. It is, therefore, imperative to conduct a pilot study that 
investigates the need for incorporating toxicogenetic analysis as part of the examinations 
performed in South African mortuaries. Information gathered from such a study would provide 
baseline data for the development of further genetic assays targeting genes known to be 
associated with the pharmacokinetics of drugs in the body, in a South African context. Such an 
analysis may be incorporated into the autopsy procedure currently in operation at Salt River 
Mortuary, which requires that the proposed model be compatible with the existing postmortem 
investigation practices.  
 
According to the Department of Health in the Western Cape Government (2014), Salt River 
Mortuary is an M6 graded facility that receives over 3500 cases per annum. A caseload of that 
magnitude coupled with the limitation of national resources available to Western Cape’s 
Forensic Pathology Service dictates that only selected cases can be afforded an investigation 







At Salt River Mortuary, only those cases for which some evidence of exposure to drugs, 
chemicals or other substances is brought to the attention of the assigned pathologist, usually 
undergo a comprehensive toxicological investigation. In addition, cases of sudden, unexplained 
death where there are no gross pathological findings at autopsy usually undergo toxicological 
and histological examinations. In such cases, blood is the biological specimen of choice, owing 
to its advantages over other biological samples, which include the availability of a great 
magnitude of literature that can facilitate the interpretation of analytical results, and the 
numerous collection sites from which to choose (Moffat et al., 2004).  
 
Kerrigan’s (2013) review of biological specimens commonly used in forensic toxicology 
illustrated that some specimens are better suited to certain purposes (screening versus 
quantitation, or targeted drug identification) than others. However, almost all postmortem 
specimens have limitations that need to be considered in collection, analyses and interpretation. 
Some of these specimens are complex matrices, often requiring extensive preparation that is 
both expensive and time-consuming. This includes tissues like the brain and liver. Some 
specimens have limited quantitative and therefore interpretive value, and others are prone to 
postmortem putrefactive effects. While specimens such as urine provide an indication of 
exposure and have value in the case context, the use of blood – particularly peripheral blood – 
in routine postmortem toxicological analyses has been adopted globally and locally, given its 
interpretive value in most cases. 
 
Currently, when the need to perform a toxicological investigation for a case examined at Salt 
River Mortuary arises, femoral blood samples are collected into glass collection vials. These 
are either plain (have no additives) (red-top tubes) or contain sodium fluoride and potassium 
oxalate (grey-top tubes). The literature reviewed has not reported any negative effects of the 
use of potassium oxalate for blood storage (Holodniy et al.,1991); however, it has shown how 
DNA can be adversely affected by sodium fluoride (Ren et al., 2012; Podder et al., 2015; Liu 
et al. 2017). It should be noted that none of the studies performed have shown what the effect 
of having both of these compounds in a storage container are on the DNA contained in the 
blood under storage. The literature review has also highlighted the fact that no researchers have 
reported on the effect of these compounds on postmortem blood, which has been shown to be 






Nazir et al., 2011). The nature of postmortem forensic investigations is such that samples not 
taken at autopsy usually can’t be taken at a later stage when the need for them is realised, as 
the body would most likely have been released to the family of the deceased. Samples for DNA 
testing are not taken routinely in the current environment. Since we envisage that toxicogenetic 
analysis would be performed upon the interpretation of toxicological results, it is crucial to 
determine if the handling of postmortem blood specimens collected into collection tubes 
currently employed at Salt River Mortuary for the performance of toxicological analysis would 
not compromise the quality of the DNA contained in the blood in a way that renders the genetic 
material unsuitable for sequencing the genes of the target enzymes at a later stage.  
 
The outcome of such an investigation would give an indication as to whether blood samples 
currently collected at autopsy and handled in a toxicological environment are sufficient for use 
in the proposed molecular assay or whether such an assay would require the collection of blood 
samples in collection tubes specifically designed for the collection and storage of blood for the 
purpose of genetic analysis. 
 
1.6. Aim and objectives 
 
The aim of this study was, therefore, to investigate whether blood samples collected and stored 
in collection tubes intended for toxicological analysis, were suitable for use in a genetic 
analysis, following handling involved in the process of toxicological investigation. 
 
To this end, the objectives were: 
• Recruitment of 30 postmortem cases identified to have a toxicological relevance at Salt 
River Mortuary. 
• Collection of postmortem blood specimens into three types of sterile blood collection 
tubes. 
• Extraction of endogenous DNA from all the collected blood samples, before and after 
toxicological analysis. 
• Quality assessment of extracted endogenous DNA contained in all of the collected 







CHAPTER 2: MATERIALS AND METHODS 
 
2.1. Participant recruitment 
 
The study consisted of a cohort of 30 postmortem cases selected from Salt River Mortuary. A 
minimum of 30 cases was targeted to confer statistical significance to the outcome of the 
project. The mortuary is one of 17 in Western Cape, South Africa, and receives cases from the 
West Metropole of Cape Town. The study obtained ethics approval from the University of 
Cape Town’s Faculty of Health Sciences Human Research Ethics Committee – REF: 110/2017 
(Appendix A). 
 
2.1.1. Inclusion criteria 
 
Cases that were deemed relevant to the study were those whose cause of death was known or 
suspected to involve drug toxicity, which warranted the collection of blood specimens (at 
autopsy) for toxicological analysis. Cases in which there was a sudden and unexpected death 
of an adult (SUDA), and for which a history of drug use was reported, were also included in 
the study. Only those cases for which informed consent from the next-of-kin of the deceased 
was obtained were included in the study. 
  
2.1.2. Exclusion criteria 
 
Cases wherein the corpse was received in a condition that may have compromised the quality 
of the DNA, including cases of decomposition and immolation, were not included in the study. 
All cases in which the decedent was below the age of 18 years were also excluded from the 
study.  
 
2.1.3. Informed consent 
 
The description of cases received by the mortuary was reviewed daily to select relevant cases. 
For each case selected, a meeting between the researcher and the next-of-kin of the deceased 
was arranged. The meeting was conducted in a manner that upheld the declaration of Helsinki 






Fortaleza, Brazil, and was within the ethical framework previously established in-house 
(Heathfield et al., 2017). In addition to providing the next-of-kin with an information form 
(Appendix B) explaining the purpose of the study, the procedure involved, and the risks and 
benefits of the study, all of the relevant information was communicated verbally to the family 
members present in the meeting to ensure that they understood all the important aspects of the 
study. This was performed in the families’ language of choice.  
 
Conducting the meeting face-to-face also afforded the family members an opportunity to 
express the concerns they may have had about participating in the study and provided the 
researcher with a platform to answer any relevant questions. Having ensured that the family 
members fully understood the study, informed consent was formally requested from the next-
of-kin to collect a specified volume of blood from their deceased family member and to subject 
it to the experiments of the study as described to the family. Signatures from the next-of-kin 
and a witness present in the meeting were obtained if agreed upon. 
 
2.2. Sample collection 
 
For those cases for which informed consent was obtained, femoral blood specimens were 
collected from the deceased. Blood was drawn from the femoral vein of the deceased and 
transferred into one 4 mL purple-top tube (denoted by P herein) (BD Vacutainer, New Jersey, 
USA), two 4 mL grey-top tubes (denoted by G herein) (SG Vac), and into two 10 mL red-top 
tubes (denoted by R herein) (SG Vac). The volume of blood that was aliquoted into each of the 
five tubes was 4 mL. The grey-top tube (containing potassium oxalate and sodium fluoride) 
and the red-top tube (with no additives) are equivalent to the blood collection vials used at Salt 
River Mortuary for samples intended for toxicological investigations. These were, therefore, 
the primary focus of the study and feature prominently in the discussion of the study results. 
The purple-top tube (containing EDTA) is the standard tube used at Salt River Mortuary for 
genetic-based investigations and served as a control vial in the study. 
 
The unique identifier code that was given to each sample was used throughout the study to 
maintain confidentiality and to track the blood specimen collected into the tube as well as the 







2.3. Post-collection processing 
 
Following collection at Salt River Mortuary, all the blood specimens were immediately 
transported to the University of Cape Town’s Molecular Forensics’ laboratory. The samples 
were stored at 4˚C and DNA was extracted within 72 hours of sample collection from all the 
samples that would not undergo toxicological analysis, identified as the “No-tox” samples: one 
grey-top tube (G-No-tox), one red-top tube (R-No-tox), and the purple-top tube (P-No-tox) 
(Figure 2.1).  
 
The remaining grey-top tube and red-top tube (called G-Tox and R-Tox, respectively) remained 
stored at 4˚C at UCT’s Forensic Toxicology Unit laboratory until downstream toxicological 
analysis was performed (Figure 2.1). These samples were, therefore, called “Tox” samples. 
 
 
Figure 2.1: Collection of five blood samples from decedents and overview of downstream processing. 
Following the selection of a postmortem case of interest and the recruitment of the participant thereof, five femoral 
blood samples (4 mL) were collected from the deceased into three types of blood collection tubes: 1 × purple-top 
tube, 2 × grey-top tubes, and 2 × red-top tubes. The blood samples were stored at 4˚C and DNA was isolated 
within 72 hours of blood collection from one of each tube type. The remaining grey-top and red-top tubes were 
handled in a toxicological environment (at 4˚C) and DNA was extracted approximately 16 weeks after blood 







2.4. Laboratory work 
 
2.4.1. Toxicological processing 
 
In the routine work of Forensic Pathology Service at Salt River Mortuary, forensic pathologists 
may collect blood samples (together with other specimens) from cases in which drugs and or 
alcohol are suspected to have caused or contributed to death. A toxicological qualitative 
analysis is initially performed on these blood specimens to obtain a preliminary screen of 
targeted drugs of abuse if the pathologist requests. This procedure was simulated in this study. 
Within 7 days of sample collection, a volume of 500 µL of blood was aliquoted from the G-
Tox and R-Tox samples and transferred into a fresh grey-top tube to make up a total volume 
of 1 mL for each case. Sample preparation in the form of acetonitrile protein precipitation was 
performed on the aliquots, before they underwent screening by means of liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) analysis using a Shimadzu 
Prominence High Performance Liquid Chromatography (Tokyo, Japan) system coupled to a 
AB SCIEX API 3200 Q-TRAP® Mass Spectrometer (Massachusetts, USA) that operates on 
the AB SCIEX MasterViewTM software (Massachusetts, USA). The remainder of the blood in 
the Tox tubes remained under storage at 4˚C until another aliquot was taken for a simulated 
quantitative analysis. 
 
Finally, DNA extraction was performed on the Tox-samples, which was approximately 16 
weeks after the original blood collection (Figure 2.1). 
 
2.4.2. DNA Extraction 
 
DNA was extracted from all the five blood specimens collected for each case. The QiaAmp 
DNA Investigator’s Kit (Qiagen, Hilden, Germany) was used, with the slight modification of 
centrifugation at 10 285 × g instead of 6 582 × g in step 9 of the protocol. The process used 
100 µL of blood, from which DNA was isolated and eluted into 50 µL of Qiagen ATE Elution 
Buffer (this was referred to as elution 1). The elution step was repeated into a separate vial with 
another 50 µL of the Qiagen ATE Elution Buffer to produce elution 2, such that at the end of 
each DNA extraction procedure there were two 50 µL samples of isolated DNA (elution 1 and 






2.4.3. Quality assessment of the extracted DNA  
 
2.4.3.1. Assessment of the quantity and purity of DNA by spectrophotometry 
 
DNA was initially quantified using NanoDrop 2000 (Thermo Scientific, Massachusetts, USA). 
To determine the concentration of DNA in each sample, a volume of 2 μl of the sample was 
placed onto the instrument's pedestal and the concentration of DNA in the sample read from 
the system's software, NanoDrop 2000/2000c Software (Thermo Scientific, Massachusetts, 
USA).  
 
To determine the purity of the extracted DNA sample, the 260/280 and 260/230 absorbance 
ratios were noted during each concentration reading. The absorbance ratio of 260/280 provided 
an indication of the amount of proteins and peptides present in the sample, and the absorbance 
ratio of 260/230 gave an indication of the extent to which the sample was contaminated with 
impurities such as phenolic compounds, EDTA, carbohydrates, and Guanidine hydrochloride 
(Desjardins and Conklin, 2010). 
 
2.4.3.2. Assessment of the quantity and degradation of DNA by qPCR 
 
Following the manufacturer’s protocol, qPCR was set up using the Quantifiler™ Trio DNA 
Quantification Kit (Applied Biosystems, California, USA). The combined Quantifiler™ Trio 
assays separately amplify a small and a large human autosomal target, as well as a specific 
region in the human Y chromosome. The ratio of the quantification result of the small 
autosomal target to that of the large autosomal target – known as the degradation index – was 
used as an indicator of DNA degradation. The result of the quantification of the Y target was 
used to confirm if the amplified DNA belonged to a male individual as a quality measure.   
 
As suggested in the manufacturer’s user guide, DNA quantification standards were prepared 
as five serial dilutions separated by a dilution factor of 10. A duplicate of these standards was 
also prepared. Elution 2 DNA samples were used for this analysis. Molecular biology grade 






such that they were all below the concentration of 50 ng/µL, which was the upper limit of the 
calibration curve that could be plotted using the aforementioned DNA quantification standards. 
 
Thermal cycling was performed according to the manufacturer’s protocol. All 150 DNA 
samples (30 purple-top tubes + 60 (30 G-No-Tox + 30 G-Tox) grey-top tubes + 60 (30 R-No-
Tox + 30 R-Tox) red-top tubes) that were acquired for this study were analysed by qPCR. 
 
2.4.3.3. Assessment of the contamination of DNA by forensic DNA Profiling 
 
A) Preparation of DNA samples and multiplex PCR amplification  
DNA profiling was performed to assess if contamination had been introduced to samples which 
had been used for toxicological analysis.  The PowerPlex® ESI 16 System (Promega, 
Wisconsin, USA) was used to prepare multiplex PCR according to the manufacturer’s technical 
manual, with the only deviation being that for every reagent, one quarter of the reagent volumes 
were used to prepare the required master mix. This was in accordance with the manufacturer’s 
approval and internal validation.  
  
Appropriate aliquots of DNA were taken from the stock DNA samples (extracted from the Tox 
samples only) to prepare DNA dilutions with a concentration of 0.5 ng/μl for each sample. A 
no-template control (NTC) PCR reaction mixture was also prepared by adding MBG water into 
the prepared master mix in the place of DNA. The instructions provided in the technical manual 
were followed to perform PCR on a BioRad (California, USA) T100 thermal cycler system. 
The multiplex system amplified the following loci: Amelogenin, D3S1358, D19S433, 
D2S1338, D22S1045, D16S539, D18S51, D1S1656, D10S1248, D2S441, TH01, vWA, 
D21S11, D12S391, D8S1179, and FGA. 
 
B) Resolution and detection of amplicons by capillary electrophoresis  
Following PCR, each sample was added into an Applied Biosystems MicroAmp® optical 96-
well plate containing WEN Internal Lane Standard 500 and Hi-Di™ formamide (Promega, 
Wisconsin, USA) as recommended in the technical manual. The injection time was set at 5 
seconds, the injection voltage at 3 kV, and the run time at 1 500 seconds before the samples 






capillary electrophoresis were analysed using the Applied Biosystems GeneMapper v4.1 
software. 
 
2.4.3.4. Assessment of the quality of DNA by Sanger sequencing 
 
The overall aim of the study was to test whether blood specimens that are taken to toxicology 
laboratories for a toxicological analysis could subsequently be used to extract DNA that is of 
sufficient quality to perform a toxicogenetic analysis. The toxicogenetic analysis of interest in 
this case is one that examines the sequence of CYP2D6, which has nine exons. Primers that 
amplify these exons were designed in-house in a parallel study. Study case 22 was selected for 
this experiment and 22G-Tox and 22R-Tox were the DNA samples that were used. (The prefix 
before the sample type denotes the study case number. This kind of notation is used throughout 
this text). 
 
A) Amplification of the exons of CYP2D6 using the designed primers 
Forward and reverse primers were prepared to amplify a target segment of the DNA, and Table 





































A Part of 1 GCCATCATCAGCTCCCTT Forward 18 55.6 54.9 439 
 CCCAAACCTGCTTCCCCTT Reverse 19 57.9 57.9 
B Part of 1 CCCTACCAGAAGCAAACA  Forward 18 50.0 52.0 597 
 CCTATTTGAACCTTGGACGA Reverse 20 45.0 52.1 
C Part of 1 CTTCCACCTGCTCACTCC Forward 18 61.1 55.3 314 
 TCTGTCTCTGTCCCCACC Reverse 18 61.7 56.1 
D 2 and 3 GTGGATGGTGGGGCTAAT Forward 18 55.6 54.6 483 
ACTCCTCGGTCTCTCGCT Reverse 18 61.1 57.7 
E 4 CCCGTTCTGTCTGGTGTAG Forward 19 57.9 54.9 266 
 AGCCTCCCCTCATTCCTC Reverse 18 61.1 56.3 
F 5 and 6 GTTCTGTCCCGAGTATGC Forward 18 55.6 52.7 334 
 CCTGACACTCCTTCTTGC Reverse 18 55.6 52.9 
G 7 CATAGGAGGCAAGAAGGAG Forward 19 52.6 52.1 382 
 TGGTGGCATTGAGGACTA Reverse 18 50.0 53.1 
H 8 ATCCTAGAGTCCAGTCCC Forward 18 55.6 52.3 534 
 ACTACCACATTGCTTTATTGTAC Reverse 23 34.8 51.0 
I 9 TATCACCCAGGAGCCAGG Forward 18 61.1 56.3 520 
 CCCACATGCCAGGACAAT Reverse 18 55.6 55.4 
Note: Targets A, B, and C are not full-length exons; they are parts of exon 1 of CYP2D6, 
combining to give the full length of the exon. Targets D and F are stretches of DNA 
incorporating exons 2 and 3, and exons 5 and 6 of CYP2D6, respectively. In this study, these 
DNA segments are called “targets” (followed by the designated alphabet) for convenience. 
 
For each of the targets listed in Table 2.1, DNA of 50 ng was amplified in a total volume of 25 
µL, with 10µM of each primer (Integrated DNA Technologies, Iowa, USA) and 2X GoTaq 
Green Master Mix (Promega). Elution 1 DNA samples were used in this analysis.  
 
The PCR tubes were placed into the wells of the BioRad T100 thermal cycler such that the 
targets would be amplified using the following cycling conditions: 5 minutes of initial 






at 62.9˚C (for primers A, C, and I) or 55.3˚C (for the rest of the targets) for 30 seconds, 30 
cycles of elongation at 72˚C for 30 seconds, and, finally, 5 minutes of final extension at 72˚C. 
 
To determine if all the target segments were successfully amplified by PCR, agarose gel 
electrophoresis was performed. A 1.5% w/v agarose gel was prepared by dissolving agarose 
powder (Sigma-Aldrich, Missouri, USA) into Tris-Borate-EDTA (TBE) buffer, after which 
0.01% v/v of SYBR® Safe nucleic acid gel stain (Thermo Fisher Scientific, Massachusetts, 
USA) was added to the resultant solution. The resultant gel was placed in a BioRad 
electrophoretic tank filled with TBE buffer and the PCR products were loaded (5 µL) into the 
wells. Electrophoresis was performed for 80 minutes at 100 Volts and 400 mAmp. 
 
B) Determining the sequences of the amplified PCR products by Sanger sequencing 
Sanger sequencing was performed on PCR products. This necessitated a preparatory post-PCR 
clean up step in which primers, deoxynucleotide triphosphates (dNTPs), and chaotropic salts 
were filtered out of the samples by following the instructions of the manufacturer – 
Nucleofast® 96 PCR (Macherey-Nagel, Düren, Germany). BigDye Terminator v3.1 cycle 
sequencing kit (Applied Biosystems, California, USA) was used for sequencing. The 
manufacturer’s protocol was followed to sequence the forward and reverse complements of 
targets A, B, C, E, and I; the reverse complements of targets D and H, and the forward 
complements of targets F and G. This procedure was performed by the University of 
Stellenbosch’s Central Analytical Facility. 
 
The resultant sequences were viewed using the ChromasLite version 2.4.4 software 
(Technelysium, South Brisbane, Australia). The BioEdit version 7.2.6 Sequencing Alignment 
Editor and Analysis Program (Hall, 1999) was used to compare the obtained sequences to the 
reference CYP2D6 sequence, where multiple sequence alignment was performed using 
ClustalW with a bootstrap of 1000. The variants on the sequences were noted and their 
functional significance assessed by comparison to the variants documented on the Ensembl 










2.5. Analysis of results 
 
The data produced from the experiments described above was divided into three datasets based 
on the blood collection tubes that were used: purple-top, grey-top, and red-top tubes. The data 
was also divided according to the post-collection processing that the samples were subjected 
to, splitting the data into two categories: Tox samples and No-Tox samples. Each of the 30 
cases was represented in terms of these groups of data, which formed the basis for the analysis 
that was carried out. The overall analysis was based on the comparison of these datasets and 
statistical tests were employed to compare data in some of the variables investigated. 
 
The Stata® Data Analysis and Statistical Software (StataCorp, Canada, USA) was used for 
statistical analysis. The Shapiro Wilk test was performed to assess if the data was normally 
distributed. To test if there was a significant difference between the median values of the 
compared datasets, the Wilcoxon Signed Rank test was used. The tests were performed for 
DNA concentration, sample purity, and degradation index, where the level of significance (𝛼) 























CHAPTER 3: RESULTS 
 
3.1. DNA quantification by qPCR 
 
For all the blood specimens that were collected, DNA was extracted and quantified by qPCR. 
The aim of this analysis was to assess if the storage of blood specimens in the different 
collection tubes affected the quantity of the DNA in the blood, and whether handling samples 
in a toxicological environment has any adverse effect on endogenous DNA. The results of this 
analysis are presented in Figure 3.1. Of the three DNA targets (large autosomal, small 
autosomal, and Y chromosome) amplified by the Quantifiler™ Trio DNA Quantification 
system, the large autosomal target was chosen for this analysis, as its size (214 bp) is closest to 
the lengths of the sequences targeted in the intended toxicogenetic analysis. 
 
 
Figure 3.1: DNA Concentration assessed by qPCR. Postmortem blood samples (4 mL) were collected into three 
types of blood collection tubes: purple-top (P), grey-top (G), and red-top (R) tubes. The blood samples were stored 
at 4˚C and DNA was isolated within 72 hours of sample collection from the No-Tox samples. The G-Tox and R-
Tox tubes were handled in a toxicological environment (at 4˚C) and DNA was extracted approximately 16 weeks 
after blood collection. The QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) was used for DNA 
extraction. The DNA samples were stored at 4˚C until the Quantifiler™ Trio DNA Quantification Kit (Applied 
Biosystems, California, USA) was used to quantify human DNA on a 7500 Real-Time PCR System (Applied 
Biosystems, California, USA). 
 
The effect of the additives in the tubes (or lack thereof in the red-top tubes) was assessed by 
separating the tubes into “Tox” and “No-Tox” categories and performing an inter-tube type 
comparison within each category. The researchers noted an abnormally high DNA 






















concentration for 06R-No-Tox (233.4 ng/µL). However, because the comparison between the 
different groups of samples was based on median concentrations, the anomalous concentration 
did not affect the overall analysis of the data. For the No-Tox group, the red-top tubes produced 
DNA samples whose median concentration was significantly higher than those of the P-No-
Tox (p = 0.049) and G-No-Tox (p = 0.009) samples. The R-No-Tox samples had DNA 
concentrations higher than all of the groups analysed in the study, with a median concentration 
of 25.8 ng/µL. Figure 3.1 also shows that the median concentrations of the purple-top (20.9 
ng/µL) and the grey-top (20.3 ng/µL) tubes were not significantly different (p = 0.530). 
 
However, when the Tox samples were compared, the grey-top tubes (median = 22.9 ng/µL) 
were shown to give DNA samples that were significantly higher (p = 0.002) in concentration 
than the red-top tubes (median = 9.9 ng/µL). The R-Tox samples produced the lowest DNA 
concentrations out of all the groups that were analysed by qPCR. 
 
When intra-tube type analysis was performed, the R-No-Tox group was found to produce DNA 
concentrations that were significantly higher (p < 0.001) than those of the R-Tox group median. 
When the grey-top tubes were compared, the reverse of what was seen with the red-top tubes 
was observed: the G-Tox group produced a median concentration of 22.9 ng/µL, which was 
higher than the 20.3 ng/µL of the G-No-Tox group, but this difference was not significant (p = 
0.614). 
 
The gross concentration of nucleic acid content in all of the samples was also assessed by 
spectrophotometry, the results of which are presented in the supplementary data (Appendix C, 
Section C.1). Here, trends similar to those observed in qPCR quantification were seen in that 
the R-No-Tox tube produced the highest DNA concentration and the grey-top tubes as well as 
the purple-top tube produced DNA concentrations that were not significantly different (Figure 
S1). The major difference between the two datasets, however, is that the R-Tox tube produced 
the second highest median concentration of DNA when assessed by spectrophotometry, which 










3.2. Assessment of the contamination of DNA by forensic DNA profiling 
 
Forensic DNA profiling is normally performed for the purpose of identification, where allele 
peaks in one ‘unknown’ DNA profile are compared to allele peaks in another DNA profile of 
known origin. However, in this study, the DNA profiles were produced solely to see if a mixed 
profile would be observed in the electropherograms produced from DNA samples whose 
source blood had been handled in a toxicology laboratory – an environment whose major 
precautionary focus is not the contamination of samples with extraneous DNA. 
 
No DNA profile was observed for the negative control sample (data not shown). This is taken 
as an assurance that if DNA contamination were to be observed for any of the study cases in 
the form of a profile mixture, it would not have been introduced in the process of conducting 
the analysis. No DNA profile mixture was observed in any of the electropherograms examined 
for this analysis. Figure 3.2 is portion of a DNA profile for one of the study cases and is 
presented as an example of the lack of contamination/DNA profile mixture asserted above. A 
full DNA profile is not shown here to protect the identity of the participant.  
 
 
Figure 3.2: A portion of a DNA profile for one of the study cases. Postmortem blood samples (4 mL) were 
collected into two types of blood collection tubes: grey-top and red-top tubes. The blood samples were handled 
in a toxicological environment (at 4˚C) and DNA was extracted approximately 16 weeks after blood collection 
using the QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany). The PowerPlex® ESI 16 System 
(Promega, Wisconsin, USA) was used to amplify 16 STR markers on the isolated DNA, 10 of which are shown 
in the figure. The samples were run at 60 ˚C on a Genetic Analyser 3130 xl (Applied Biosystems, California, 
USA) with the following running conditions: injection time – 5 seconds, injection voltage – 3 kV, and run time – 







It is worth noting that instrumental anomalies (pull-ups and dye blobs) were observed in many 
of the electropherograms, however, all of these artefactual peaks were accounted for and their 
sources identified. The handling of samples in a toxicological environment, therefore, did not 
cause contamination of the study samples with extraneous human DNA. 
 
3.3. Assessment of DNA purity by spectrophotometry 
 
Spectrophotometry was also used for quality assessment, wherein the absorbance ratios 
260/280 and 260/230, indicating the contamination of isolated DNA samples by peptide 
molecules and chaotropic salts, respectively, were recorded to determine the effect of the 
different additives in the different collection tubes on the purity of the isolated DNA (purple-
top versus grey-top versus red-top tubes). The analysis also examined if the handling of 
samples in a toxicology laboratory reduced the purity of the isolated DNA (Tox versus No-Tox 
samples).  
 
For both 260/280 and 260/230, a DNA sample was considered to be pure only if the absorbance 
ratio was above 1.8 (denoted by a dashed line in Figure 3.3.A. and Figure 3.4.A.) (Desjardins 
and Conklin, 2010). Therefore, for this analysis, each sample was examined to see if its 
absorbance ratio passes this threshold, above which purity was declared. For 260/280 (Figure 
3.3) and 260/230 (Figure 3.4) absorbance ratios, the scatter of the 30 samples in each group is 
represented in the chart shown in A, while the bar graph in B shows the proportion (n/30) of 










Figure 3.3: Absorbance ratio 260/280 assessed by spectrophotometry. A: the scatter of the 30 samples in each 
sample group; B: the percentage (n/30) of samples whose absorbance ratios were above the value 1.8 (denoted by 
a dashed line in A). Postmortem blood samples (4 mL) were collected into three types of blood collection tubes: 
purple-top (P), grey-top (G), and red-top (R) tubes. The blood samples were stored at 4˚C and DNA was isolated 
within 72 hours of collection from the No-Tox samples. The G-Tox and R-Tox tubes were handled in a 
toxicological environment (at 4˚C) and DNA was extracted approximately 16 weeks after blood collection. DNA 
was extracted using the QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) and NanoDrop 2000 
(Thermo Scientific, Massachusetts, USA) was used to assess the 260/280 absorbance ratio. 
 
Figure 3.3.A shows that, regarding protein contamination, the samples from all three tube types 































Statistically, there was not enough evidence to reject the null hypothesis; the p-values for the 
comparisons of the median absorbance ratios between (i) P-No-Tox and G-No-Tox, (ii) P-No-
Tox and R-No-Tox, and (iii) G-No-Tox and R-No-Tox were 0.81, 0.334, and 0.484, 
respectively. An overall examination of these (No-Tox) samples shows that, generally, there 
were more samples that were relatively free from protein contamination than those that were 
not (Figure 3.3.B). In the group of samples with the least number of pure samples (P-No-Tox), 
70% of the samples were pure, with the other groups, R-No-Tox and G-No-Tox, having higher 
proportions of 76.7% and 83.3%, respectively.  
 
In contrast, Tox samples had relatively lower purity. This is illustrated in Figure 3.3.A by the 
data points moving away from the gridline of 2 in the Y-axis, and closer to the gridline marking 
1.5. This is further confirmed by the purer group (G-Tox) only having 36.7% of its samples 
passing the mark of 1.8, while this proportion was 13.3% for the R-Tox group (Figure 3.3.B). 
 
Regarding contamination with chaotropic salts (260/230), all the samples had relatively lower 
purity (Figure 3.4). In contrast to what was seen in 260/280, when the G-No-Tox and R-No-
Tox samples were compared to the Tox samples regarding contamination with chaotropic salts, 
the samples that were handled in a toxicological environment appeared to have higher purity. 
The No-Tox samples were dominated by the P-No-Tox group, with 26.7% of its samples being 
pure, while the G-No-Tox and the R-No-Tox groups had 23.3% and 13.3% of their samples, 
respectively, being pure. Of the Tox groups, the grey-top tubes produced the higher proportion 
of pure DNA samples: 40%. This was also the highest proportion recorded for the whole 
analysis, which is an indication that, generally, there were more samples that were impure than 











Figure 3.4: Absorbance ratio 260/230 assessed by spectrophotometry. A: The scatter of the 30 samples in each 
sample group; B: The percentage (n/30) of samples whose absorbance ratios were above the value 1.8 (denoted 
by a dashed line in A). Postmortem blood samples (4 mL) were collected into three types of blood collection 
tubes: purple-top (P), grey-top (G), and red-top (R) tubes. The blood samples were stored at 4˚C and DNA was 
isolated within 72 hours of collection from the No-Tox samples. The G-Tox and R-Tox tubes were handled in a 
toxicological environment (at 4˚C) and DNA was extracted approximately 16 weeks after blood collection. DNA 
was extracted using the QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) and NanoDrop 2000 


































3.4. Assessment of the degradation of DNA by qPCR 
 
The extracted DNA was quantified using qPCR to determine the degradation index, as a means 
to assess the quality/integrity of DNA in each sample collected. Since degradation index in this 
context is defined as the concentration of the small autosomal target divided by the 
concentration of the large autosomal target, the principle of this analysis is such that if the 
degradation index is equal to or less than 1, it implies that the small autosomal target was not 
amplified preferentially, which is indicative of DNA which is not degraded. Presented in Figure 
3.5 are the median degradation indices and 95% confidence intervals for all the sample groups 
analysed. 
 
It was noted that all the degradation indices were below 1 (denoted by a dashed line in Figure 
3.5), suggesting an absence of degradation in all of the groups analysed. However, a large 
variability between the groups was seen: the median degradation indices in the red-top tube 
samples (0.80 for R-No-Tox and 0.68 for R-Tox) were significantly lower than those of the 
grey-top tube samples (0.87 for G-No-Tox and 0.84 for G-Tox) for both the No-Tox (p = 0.009) 
and the Tox (p < 0.001) groups. The median degradation index of the purple-top tubes (0.85) 
was not significantly different to that of the G-No-Tox group (p = 0.797) but significantly 









Figure 3.5: Degradation indices of isolated human DNA. Postmortem blood samples (4 mL) were collected 
into three types of blood collection tubes: purple-top (P), grey-top (G), and red-top (R) tubes. The blood samples 
were stored at 4˚C and DNA was isolated within 72 hours of collection from the No-Tox samples. The G-Tox and 
R-Tox tubes were handled in a toxicological environment (at 4˚C) and DNA was extracted approximately 16 
weeks after blood collection. The QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) was used for DNA 
extraction. The DNA samples were stored at 4˚C until the Quantifiler™ Trio DNA Quantification Kit (Applied 
Biosystems, California, USA) was used to determine the degradation indices of the endogenous DNA on a 7500 
Real-Time PCR System (Applied Biosystems, California, USA). 
 
Intra-tube type comparison of degradation indices was also performed to assess the effect that 
the handling of blood samples in a toxicological environment has on DNA. There was no 
significant difference (p = 0.829) in the median degradation index between the grey-top tube 
samples that were handled in a toxicology laboratory (0.84) and those that were not (0.87). In 
contrast, the median degradation index of the R-Tox samples (0.68) (which was the lowest for 
all the groups that were examined in this analysis) was significantly lower (p < 0.001) than that 
of the R-No-Tox samples (0.80). Despite this observed intra-tube difference between R-Tox 
and R-No-Tox, it was noted that the red-top tubes produced the lowest degradation indices for 
the whole analysis, regardless of whether or not the samples were handled in a toxicological 










3.5. Assessment of the quality of DNA by Sanger sequencing 
 
For this experiment, DNA sequences were presented in the form of electropherograms, and the 
comparisons were made on the basis of peak shape, background noise, and the ability of the 
software to accurately call the base represented by the peaks (which is influenced by peak shape 
and background noise). However, agarose gel electrophoresis was first performed to assess 
whether the CYP2D6 targets were successfully amplified and whether there was any difference 




Figure 3.6: PCR amplification of all the CYP2D6 targets for the GT and RT samples. Postmortem blood 
samples (4 mL) were collected into two types of blood collection tubes: grey-top (GT) and red-top (RT) tubes. 
The blood samples were handled in a toxicological environment (at 4˚C) and DNA was isolated approximately 
16 weeks after collection using the QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany). Aliquots of the 
extracted DNA were amplified by PCR on a BioRad T100 thermal cycler (California, USA) using primers 
designed in-house and a GoTaq® Green Master Mix (Promega, Wisconsin, USA). The amplicons were resolved 
in a 1.5% w/v agarose gel, where, for gel A, the wells were loaded as follows: well 1(MM): Quick-Load® 50 bp 
Ladder (New England Biolabs, Massachusetts, USA), and well 2–10: targets A–I for the R-Tox sample. For gel 
B, the wells were loaded as follows: well 1–9: targets A–I for the G-Tox sample, well 10 (NTC): no template 
control sample, and well 11 (MM): Quick-Load® 50 bp Ladder. Electrophoresis was performed for 80 minutes 
at 100 V and 400 mAmp. 
 
As can be seen in lane “NTC” of gel B in Figure 3.6 – where the no template control sample 
was loaded – there were no bands produced for the sample that served as a negative control, 
suggesting that the procedure that the samples were taken through did not introduce 
contamination in the form of human DNA. All the 9 targets (A–I) were successfully amplified 






produced, for every target, there was no remarkable difference in the amount of DNA that was 
amplified between the G-Tox sample and the R-Tox sample. 
 
For the 9 targets that were examined by Sanger sequencing, the DNA sequence produced with 
DNA from the G-Tox sample was compared to the DNA sequence produced with DNA from 
the R-Tox sample (Figure 3.7). Represented with the electropherograms shown in Figure 3.7 
are the (I) forward and (II) reverse complements of target A. The top panel shows the 
electropherogram that was obtained when sequencing was performed using DNA from the G-
Tox (GT) sample and the bottom panel shows the electropherogram that was obtained when 

































II: Reverse orientation  
 
Figure 3.7: A portion of the DNA sequence of target A. Postmortem blood samples (4 mL) were collected into 
two types of blood collection tubes: grey-top (GT) and red-top (RT) tubes. The blood samples were handled in a 
toxicological environment (at 4˚C) and DNA was isolated approximately 16 weeks after collection using the 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany). The targets of CYP2D6 were amplified by PCR 
using primers designed in-house. The sequences of the (I) forward complement and the (II) reverse complement 
of target A were determined by a Sanger sequencing method that utilised the BigDye Terminator v3.1 Cycle 







Looking at the background noise in Figure 3.7.I, it can be seen that the R-Tox sample produced 
an electropherogram of similar quality compared to the one produced by the G-Tox sample.  In 
contrast, Figure 3.7.II shows two electropherograms in which the DNA sequence produced by 
the R-Tox sample is substantially better in quality than that produced by the G-Tox sample. 
The difference between the two electropherograms is so drastic that numerous inconsistencies 
in terms of the bases called by the software were observed. This is especially demonstrated by 
the three artefactual SNPs produced in the GT electropherogram as a result of its poor quality, 
which would complicate the process of analysing the DNA sequence. When such situations 
were encountered with other comparisons (Appendix C, Section C.2: Figure S2–S9), it was 
under this premise that the quality of one DNA sequence was declared to be better than the 
other. Figure 3.8 shows the results of the comparisons made for all the targets (A–I) examined 
in the study. 
 
 
Figure 3.8: Comparison of the quality of DNA sequences between GT and RT. Postmortem blood samples (4 
mL) were collected into two types of blood collection tubes: grey-top (GT) and red-top (RT) tubes. The blood 
samples were handled in a toxicological environment (at 4˚C) and DNA was isolated approximately 16 weeks 
after collection using the QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany). The targets of CYP2D6 
were amplified by PCR using primers designed in-house. The sequences of the forward complement and the 
reverse complement of target A were determined by a Sanger sequencing method that utilises the BigDye 







As shown in Figure 3.8, the sequences from both tubes were of good quality in 57% of the 
electropherograms produced. The sequence was good quality for the R-Tox sample and poor 
quality for the GT sample in 43% of the electropherograms generated. In none of the 
electropherograms was the DNA sequence produced from the G-Tox sample of better quality 
than that produced from the R-Tox sample. 
 
3.6. Application of the toxicogenetic analysis 
 
The analysis on the basis of Sanger sequencing had shown the red-top tube to produce DNA 
samples better suited for the generation of sequence electropherograms. To test the 
applicability of this result, toxicogenetic analysis was performed using the 22R-Tox sample, 
where the assay designed in-house was applied to amplify the exons of CYP2D6, after which 
they were analysed by Sanger sequencing. The variants in the resultant sequences were noted, 
and those for which the corresponding haplotypes were determined are presented in Table 3.1. 
 











rs28371718 CYP2D6*1D C/A 2575C>A Normal 
rs774671100 CYP2D6*13 G/A 137_138insT None 
rs769157652 CYP2D6*27 G/A 3853G>A Normal 
rs28371696 CYP2D6*43 G/A 77G>A Normal 
rs77913725 CYP2D6*86 G/A 2606G>A Unknown 
 rs1135828 T/A 2610T>A 
 
A total of 29 SNPs was detected in the CYP2D6 gene of the chosen case. Of the 29 variants, 
only 6 translated into recognised haplotypes (Table 3.1). Most of the detected haplotypes 
(CYP2D6*1D, CYP2D6*27, and CYP2D6*43) do not cause a change in the “normal” activity 
of the CYP2D6 enzyme. In contrast, the presence of the CYP2D6*13 haplotype completely 
eradicates the activity of the allele on which the rs769157652 SNP is located. The rs769157652 
and rs1135828 combined to give the CYP2D6*86 haplotype, whose effect on the activity of 








3.7. Correlation analyses: assessment of the effect of period differences 
 
It should be noted that the nature of the current study is such that participants were recruited 
on different days, with the period between death and the collection of blood samples ranging 
from 0 to 7 days. Also, the extraction of DNA within 72 hours of blood collection for the No-
Tox samples made the period between death and DNA extraction relatively short when 
compared to the Tox samples, wherein the period between death and the extraction of DNA 
ranged from 7 to 99 days. To account for this difference, correlation tests were performed for 
the Tox samples to assess whether the trends observed in the results presented in this chapter 
could be ascribed to the described period differences (Appendix C). In the two sets of data that 
were generated, no correlation between time and concentration, degradation index, or 
absorbance ratio was found for both the period between death and the collection of blood 
samples (Appendix C, Section C.3), and the period between death and the extraction of DNA 
(Appendix C, Section C.4). 
 
An overview of all the analyses that were performed in the study and the results that were 
obtained is provided in Table 3.2. 
 
Table 3.2: Overview of the analyses performed and the results obtained in the study. 
Analysis/Experiment Goal Result/Highlight of the analysis 
DNA quantification by qPCR.  
 
To test the effect of the different additives in the different 
blood collection tubes on the concentration of DNA. 
DNA concentration decreased significantly in blood stored in red-
top tubes and handled in a toxicological environment while it 
remained relatively constant when stored in a grey-top tube. 
DNA quantification by 
Spectrophotometry. 
Overall, red-top tubes produced the highest DNA concentrations, 
while DNA concentration remained constant in the samples stored 
in grey-top tubes. 
Assessment of the contamination of 
DNA by forensic DNA profiling. 
To test whether handling blood collection tubes in a 
toxicological environment exposes the blood to contamination 
with human DNA. 
No DNA profile mixture was observed in any of the 
electropherograms examined for this analysis, indicating absence 
of contamination with human DNA. 
Assessment of DNA purity by 
spectrophotometry. 
To test whether any (and the extent to which) the different 
additives in the different blood collection tubes predisposes 
the collected DNA to the introduction of unwanted impurities. 
In both grey- and red-top tubes, purity (in terms of contamination 
with peptide molecules) decreased when the samples were handled 
in a toxicological environment while it decreased in terms of 
contamination with chaotropic salts under the same conditions. 
Assessment of the degradation of 
DNA by qPCR. 
To test whether the storage of blood in the different blood 
collection tubes causes DNA degradation. 
All the tube types produced degradation indices below 1. 
Degradation index tended to decrease when samples were handled 
in a toxicological environment. 
Assessment of the quality of DNA by 
Sanger sequencing. 
To test which of the blood collection tubes normally used for 
the storage toxicological samples is best suited to the storage 
of blood from which Sanger sequence is subsequently to be 
performed. 
The DNA derived from the red-top tubes produced only DNA 
sequences of good discernible quality, while the DNA derived 
from the red-top tubes produced DNA sequences of good 
discernible quality in only 57% of the instances. 
Application of the toxicogenetic 
analysis. 
To test whether samples stored in the tube type that performed 
better in the analysis above can be used for the intended 
toxicogenetic analysis. 
The sequences produced from the DNA derived from red-top tubes 
were successfully used to determine the haplotyes necessary to 
ascertain the CYP2D6 metabolic phenotype of the individual in 
question. 
Correlation analyses: assessment of 
the effect of period differences. 
To test if a correlation exists between the results observed and 
the period differences between death and blood collection, 
and between death and DNA extraction. 
No correlation between time and concentration, degradation index, 
or absorbance ratio was found for both the period between death 
and the collection of blood samples, and the period between death 







CHAPTER 4: DISCUSSION AND CONCLUSION 
 
Given that the prevalence of drug use in South Africa is one of the highest in Africa (Otu, 
2011), an examination that elucidates the extent to which certain genes contribute to drug-
related deaths may prove significant in a local forensic context. Case reports on oxycodone 
(Jannetto et al., 2002), tramadol (Levo et al., 2003), citalopram (Holmgren et al., 2004), and 
amitriptyline (Koski et al., 2006) toxicity have shown the significance of postmortem 
toxicogenetic analysis. The literature reviewed indicated that there is value of a toxicogenetic 
assay to demonstrate the inadvertent contribution of an individual’s genetic make-up in the 
production of ADRs. The debate about the inclusion of this test as a standard component of 
postmortem investigation is centered on whether or not it is necessary, feasible and applicable 
as a routine test (Koski et al., 2006). 
 
No information has been reported on the pre-analytical process the examination involves. This 
is crucial, as a successful integration of toxicogenetic analysis would include a tested, validated 
and standardised approach of the pre-analytical process for both the toxicological and genetic 
components of the examination. The careful consideration of this aspect of the toxicogenetic 
analysis is informed by the knowledge that the majority of laboratory errors have little to do 
with validated instrumental analyses, but rather derive from issues in the pre-analytical process 
(Skopp, 2004). 
 
This study aimed to address this by looking at one of the most important aspects of the pre-
analytical process: whether the collection and post-collection processing of the samples 
handled in a toxicological environment compromise the quality of the DNA in such a way that 
it cannot be used for the intended subsequent genetic analysis. Genetic analyses were utilised 
for this purpose, the results of which are discussed below. 
 
4.1. DNA quantification 
 
The quantification of extracted DNA by qPCR showed that the red-top tubes that had not 
undergone toxicological analysis produced the highest DNA yield out of all the groups that 
were compared. This was even higher than the control group – the purple-top tube samples. 






distinguishing factor between them. The mechanism of how this takes place was not 
investigated in the current study and can only be hypothesised from what was observed and 
what is known about the tubes used in the study. A possible explanation for the variation in 
DNA concentration in the different tube types is that the additives in the purple-top tubes and 
the grey-top tubes are involved in a process that results in the structural damage/conformational 
change of DNA such that it cannot be amplified optimally. In the case of the grey-top tubes, 
this supposition is supported by studies that have postulated that the fluoride ion denatures 
DNA at the level of the secondary structure (Liu et al., 2017).  
 
Interestingly, the red-top tube produced the lowest DNA concentration when subjected to 
toxicological conditions, whereas there was no significant change in concentration in the grey-
top tubes when they were handled in a toxicological environment. This, again, can be attributed 
to the red-top tube’s lack of additives. Authors such as Nazir et al. (2011) and Johnson and 
Ferris (2002) have argued that the nucleases that are released during the process of cell lysis in 
postmortem blood result in DNA fragmentation (Johnson and Ferris, 2002; Nazir et al., 2011). 
The EDTA contained in purple-top tubes prevents DNA fragmentation through the chelation 
of Mg2+ (Lahiri and Schnabel, 1993), which is required by some nucleases as a cofactor. In the 
grey-top tube, potassium oxalate acts as an anti-coagulant, while the activity of sodium fluoride 
is centred on its ability to inhibit the activity of microorganisms such as Candida albicans and 
Escherichia coli (Yajima et al., 2006). 
 
The red-top tube is a plain vacutainer and, therefore, has no preventative measure against 
biocatalysis and/or microbial action, both of which may contribute to the degradation of DNA 
and the observed reduction in DNA concentration upon handling in a toxicological 
environment (Nakao and Ogata, 1963). The argument of uninhibited microbial activity in the 
red-top tubes was supported by an observation made when DNA was quantified using 
spectrophotometry (Appendix C, Section C.1.). In the said analysis, the red-top tubes before 
and after toxicological analysis produced the two highest median DNA concentrations for the 
whole analysis (Figure S1). Since quantification with qPCR (which targets only human DNA) 
showed that DNA in the red-top tubes reduces significantly when handled in a toxicological 
environment, the observation made when spectrophotometry was applied suggests that the high 
DNA content that was detected in the red-top tube after toxicological analysis was not 100% 






originally present in the blood and that of the microorganisms whose growth is uninhibited in 
the specimen. This is in line with the fact that spectrophotometry does not have a mechanism 
for distinguishing DNA from different species; it quantifies all the DNA present in a sample.  
 
The similarity of concentrations between the grey-top tubes that were handled in a toxicological 
environment and those that were not can also be linked to microbial activity in the blood 
contained in the tubes. We postulate that the limited microbial activity in the grey-top tubes 
accounts for the observed consistency in DNA yield in the sense that there is restricted 
microbial growth affecting the human DNA in the blood. This was also confirmed in the 
spectrophotometric DNA quantification wherein the DNA obtained on samples that had 
undergone toxicological analysis was similar in concentration to that obtained for samples that 
had not been handled in a toxicology laboratory. Further research is required to test if the 
unhindered microbial activity has deleterious effects on postmortem blood and whether such 
an effect would substantially be mitigated by the inhibition exerted by sodium fluoride on 
certain species of microorganisms. 
 
It must be noted, however, that regardless of the variation in concentration seen between 
different tube types and handling conditions, the concentrations obtained were sufficient to 
perform PCR, which is an essential step in the procedure of toxicogenetic analysis. 
 
4.2. Assessment of the contamination of DNA by forensic DNA profiling 
 
Blood specimens sampled for toxicological analysis are handled in a chemistry-based 
environment, which is not specifically designed for preserving the integrity of DNA. As such, 
to test whether the blood samples that underwent toxicological analysis had been contaminated 
with the DNA of another individual, forensic DNA profiling was performed on the Tox 
samples. It was expected that if any of the samples had been contaminated with DNA from 
another human, this would be indicated by the presence of more than two allele peaks in more 
than one locus of the generated DNA profile. 
 
The study found that the handling of blood samples in a toxicological environment did not 
result in the contamination of the blood with extraneous DNA. The absence of DNA 






laboratory is not particularly concerned about the contamination of samples with DNA, 
laboratories working with biological specimens generally take precaution measures against 
human skin making contact with human blood specimens, as it is a health hazard. Toxicology 
laboratories are not an exception to this. In addition, biological specimens are usually sampled 
within biosafety cabinets to reduce risks to the analyst. This is an important finding because 
the DNA used in a toxicogenetic analysis must be free from DNA contamination, as the 
analysis is centered on analysing the sequence of the decedent’s DNA to determine the 
corresponding metabolic phenotype. 
 
We, therefore, recommend the performance of DNA profiling as a quality assurance step going 
forward. That is, DNA profiling should be performed prior to use of handled samples to 
distinguish any contamination with extraneous DNA before more expensive PCR and 
sequencing tests are performed. This is suggested as toxicology specimens may be sampled 
multiple times for both screening and quantitative analyses. This was only performed twice in 
this study. Therefore, while the samples in this study were not contaminated, samples in the 
future might be handled by different people in slightly different conditions, so we recommend 
this step for future samples so that if a mutation is found, then it can be attributed to the 
decedent and not a lab personnel. 
 
4.3. Assessment of purity by spectrophotometry 
 
When the purity of blood samples was assessed, the analyses of proteins and chaotropic salts 
presented results with opposing trends: for the assessment of contamination with proteins, 
samples handled in the toxicological environment decreased in purity; however, an increase in 
purity was observed in Tox samples when an examination for contamination with chaotropic 
salts was performed. Because absorbance ratio 280/260 is a function of DNA concentration, 
the reported significant decrease in DNA concentration for the red-top tube samples can be 
used to explain the observed decrease in purity. 
 
In all of the groups examined, however, the purity in the red-top tubes was constantly lower 
than that observed for the grey-top tubes. The lack of additives in the red-top tubes cannot be 
used as an explanation for the observed lower purity, as purple-top tubes (which have EDTA 






with peptide molecules). While the investigation into the cause of the variation observed in 
purity between different tube types was beyond the scope of this study, the potential effects of 
impurities in DNA samples could not be ignored.  
 
The manner and extent to which high content of peptide molecules affects the process of 
toxicogenetic analysis is not known. Salts, ionic detergents, and phenols are known PCR 
inhibitors (Bessetti, 2007), some of which are reflected in the 260/230 absorbance ratio 
(Desjardins and Conklin, 2010). This is important to note because the procedure of the 
proposed toxicogenetic analysis involves a PCR step. Samples that have a high content of one 
or more of the compound types cited above, therefore, would not be favourable for the said 
genetic assay. However, such a premise implies that DNA samples from the red-top tubes – 
which were significantly lower in purity when compared to the grey-top tubes – would be 
amplified less efficiently in the PCR step. Interestingly, however, there was no apparent 
difference in the bands (in an agarose gel) representing amplicons produced by PCR from the 
grey-top and red-top tube samples (Figure 3.6). 
 
4.4. Assessment of the degradation of DNA by qPCR 
 
The results of the analysis that examined degradation index in this study suggested that all the 
sample groups produced DNA that was not degraded over the study period. The variation that 
was observed in degradation index existed within the range of non-degraded DNA. However, 
this variation was significant between the red-top tubes (Tox and No-Tox samples) and 
between the red-top tube group and the other tube types. The variation, therefore, cannot be 
neglected. While a degradation index above 1 suggests that the assay used for amplification 
was better able to amplify the smaller DNA target, indicative of DNA fragmentation, a 
degradation index substantially below 1 suggests that the larger DNA target was amplified 
preferentially. This cannot be read to signify DNA fragmentation.  
 
Although no significant difference existed between the degradation indices recorded for the 
grey-top tubes before and after toxicological analysis, a decrease in this value was still noted 
in the Tox sample group, as was the case for the red-top tubes. This increase in the preferential 
amplification of the larger fragment when samples were handled in a toxicological environment 






study in which this trend – a similar change (increase or decrease) between the Tox and No-
Tox samples for both the grey-top and the red-top tubes – was noted, was in the assessment of 
the purity of the DNA. The reason for the preferential amplification of the large autosomal 
target was not investigated in the current study, and it is not known whether it has any 
association with DNA purity. However, the cause could be hypothesised to be due to different 
GC contents for the large autosomal target and the small autosomal target, and the amplification 
conditions being slightly favourable to the amplification of the large target as a result of that. 
 
What is denoted by the significant difference in the degradation index between the red-top 
tubes and the other tube types is that the presence of additives in the purple-top and grey-top 
tubes reduces the degree to which this phenomenon (of preferential amplification of the large 
autosomal target) occurs. Of utmost importance for the researchers, however, is whether or not 
and/or the extent to which this phenomenon negatively affects the ability to use the stored DNA 
for the intended toxicogenetic analysis – a question that was answered by the results of the 
analysis discussed below. 
 
4.5. Assessment of the quality of DNA by Sanger sequencing 
 
The toxicogenetic analysis for CYP2D6 consists of three components: (1) amplifying the 
investigated DNA using the designed primers, (2) determining the sequence of the amplified 
segments by Sanger sequencing, and (3) analysing the sequences to determine the metabolic 
phenotype encoded by the gene. The aim of this analysis was to test whether it was possible to 
perform these three procedures on DNA derived from Tox samples. This is because it is 
envisaged that the designed toxicogenetic analysis would be performed following toxicological 
analysis, and most likely on samples retrieved from a toxicology laboratory. 
 
For more than half of the electropherograms produced for this analysis, no substantial 
difference in sequence quality was observed between the G-Tox and R-Tox samples (Appendix 
B, Figure S1 – S8). All of these electropherograms were intelligible.  However, the results also 
showed that in close to a half of electropherograms produced, the sequences were better in the 
samples from the red-top tube. Overall, the quality was poor in close to a half of the 
electropherograms produced by grey-top samples, while all of the electropherograms produced 






This provides an answer to the study question, as it shows that blood samples collected and 
stored in red-top tubes are suitable for use in a genetic analysis, following handling involved 
in the process of toxicological investigation over a period of 16 weeks. However, given the 
observed decline in DNA quantity in the red-top tubes, and the contention that it is due to 
prolonged exposure to microorganisms and nucleases, further studies are required to 
investigate if the assertion above will still hold true after a year’s period. 
 
The current study did not investigate the underlying factors for the observations made. 
However, extrapolating from previous studies, the poor performance of the grey-top tubes in 
Sanger sequencing can be attributed to the presence of sodium fluoride in the vial. Sanger 
sequencing employs PCR to integrate deoxynucleotides into a growing DNA chain, the 
mechanism of which is heavily reliant on a magnesium ion (Blanchard et al., 1993). The 
fluoride anion is known to have a strong interaction with the divalent magnesium cation (Collys 
et al., 1990). Therefore, aside from fluoride’s reported destructive effect on the structure of 
DNA (Liu et al., 2017), the anion may also interfere with the amplification of DNA through its 
interaction with the magnesium cation. This supports the argument made above: the lower 
DNA concentration observed in the purple-top and grey-top tubes before toxicological analysis 
is partly due to fluoride’s and EDTA’s interference with the process of quantification. Given 
the indispensability of magnesium to the process of PCR (Blanchard et al., 1993), the anionic 
properties of fluoride (Collys et al., 1990), and the known chelating effect of EDTA to metallic 
ions (Klodos and Skou, 1975), it is reasonable to suggest that this interference occurs at the 
level of amplification. 
 
4.6. Application of the toxicogenetic assay 
 
The overall metabolic phenotype assigned to the individual whose gene is under examination 
is dependent on the identified haplotypes. For case 22, the majority of haplotypes suggested a 
normal (extensive metaboliser) enzyme activity. However, this is heavily impacted by the 
presence of the CYP2D6*13 haplotype, which is known to completely eradicate the enzyme’s 
activity (Panserat et al., 1995). The variation in this haplotype occurs at exon 1 of CYP2D6, 
wherein its hybridisation with CYP2D7 results in the insertion of an additional thymine 
nucleotide at position 227, thereby causing a shift in the reading frame and a premature 






other haplotype found on the same allele as the CYP2D6*13 haplotype is located. However, 
since this SNP was heterozygous in the investigated case, the nullification of enzyme activity 
caused by the CYP2D6*13 haplotype does not affect the function of the alternate allele. 
 
Another important haplotype noted was CYP2D6*86, whose effect on the activity of the 
CYP2D6 is not known (Dodgen et al., 2013). If this haplotype exists on the same allele as the 
CYP2D6*13 variant, then its effect would be cancelled, as the sequence frameshift caused by 
CYP2D6*13 outweighs any single base variation in significance. This would leave the normal 
activity on the one allele that is not affected by these variants, resulting in an extensive 
metaboliser phenotype (Sajantila et al., 2010). If, however, the CYP2D6*86 haplotype exists 
on a different allele to that of CYP2D6*13, the following possible phenotypes exist depending 
on the effect the variant has on the overall activity of the enzyme: (1) if CYP2D6*86 confers 
increased or normal activity, an extensive metaboliser phenotype would result, and (2) if 
CYP2D6*86 confers decreased activity, an intermediate metaboliser phenotype would result 
(Sajantila et al., 2010). In all possible scenarios, the metabolic phenotype can either be 
extensive metaboliser or intermediate metaboliser. However, since the exact location of the 
identified variants is not known (as segregation analysis was not performed), the presented 
phenotypes are merely suggested as the possible phenotypic outcomes based on the possible 
distribution of the detected SNPs between the two alleles.  
 
Although the lack of segregation analysis (due to no parental samples being available for the 
study) impeded the ability to ascertain the exact metabolic phenotype of the decedent in 
question, the experimental question in respect of the current study was successfully answered. 
All the information that could be collected from Sanger sequencing was successfully obtained. 
As the success of Sanger sequencing is highly dependent on the quality of DNA, this 
experiment showed that the blood sample from the red-top tube after toxicological analysis can 
yield DNA of sufficient quality to perform a toxicogenetic analysis following handling in a 
toxicology laboratory. 
 
4.7. Strengths and Limitations 
 
Two of the analyses – DNA quantification and purity assessment – performed in this study, 






did not show one tube type producing better results than another tube type; all the samples met 
the threshold of non-degraded DNA. Quality assessment by Sanger sequencing was the only 
experiment in which the red-top tube was shown to produce results favourable over those of 
the grey-top tubes. This analysis is also a simulation of the intended toxicogenetic analysis; 
therefore, it holds more weight than any other analysis performed. In other words, while blood 
stored in grey-top tubes produced DNA samples with higher purity and concentration 
compared to red-top tubes following toxicological analysis, these were outweighed by the poor 
performance of the grey-top tubes during sequencing. This study, therefore, demonstrated that 
DNA concentration and purity cannot be used as proxies for the quality of DNA as far as Sanger 
sequencing is concerned. 
 
Forensic DNA profiling showed that handling postmortem blood samples in a toxicology 
laboratory did not result in contamination with extraneous DNA. This, however, is not a 
guarantee that all blood samples retrieved from a toxicology laboratory in future will be free 
of extraneous DNA. It is under this premise that we recommend the performance of forensic 
DNA profiling as a quality assurance step prior to the performance of a toxicogenetic analysis. 
Also, the study was able to demonstrate the usability of blood retrieved from a toxicology 
laboratory for a toxicogenetic analysis, as well as highlighting the red-top tubes as best suited 
to this purpose.  
 
Such information can be utilised for guidance by practitioners (forensic pathologists, 
toxicologists, and geneticists) involved in postmortem investigation when the need to perform 
toxicogenetic analysis arises. Therefore, this study provided guidelines around the pre-
analytical process of the intended toxicogenetic analysis. Moreover, the availability of the data 
produced from this study provides an opportunity to the forensic pathology service providers 
in South Africa to expand the services they are currently rendering. This will ultimately give 
families more information about the circumstances surrounding the death of their relative, thus 
minimising the uncertainties that normally accompany cases of sudden unexpected deaths.  
 
However, despite the potentially impactful information that can be drawn from this study, some 







The inclusion criteria that was used to select cases for this study was one that excluded children 
and cases of immolation and decomposition. This presents a limitation of the application of the 
designed assay on the blood specimens originating from the aforementioned cases, as the study 
does not provide evidence showing the viability of such specimens for the assay. Also, the 
study utilised a sample size of 30 cases to confer statistical significance to the outcome of the 
research. However, a bigger sample size would be more representative of the wider South 
African population and give a better indication of how DNA is affected by the handling of 
blood samples in a toxicological environment. 
 
The extrapolations made for this study were mainly drawn from the information available about 
the effects of sodium on DNA. To the knowledge of the author, the effects of potassium oxalate 
on DNA have not been published. This study was not able to answer that question, as the grey-
top tube contains both sodium fluoride and potassium oxalate. However, for the purpose of this 
study, such an analysis was not necessary, as none of the collection tubes used to collect blood 
specimens for toxicological analysis at Salt River Mortuary contain only potassium oxalate; 
this additive is always present with sodium fluoride. It suffices to know that collection tubes 
containing sodium fluoride and potassium oxalate have an effect that renders DNA of poor 
quality for Sanger sequencing when compared to those that do not contain these additives. 
 
The authors also acknowledge that the differences between the Tox and No-Tox samples were 
reported as being as a result of handling the other cohort of samples in a toxicological 
environment. However, it should be noted that DNA was extracted from the Tox samples 
approximately 16 weeks after blood collection, whereas DNA was extracted from the No-Tox 
samples within only 72 hours of blood collection. This makes time an undeniable factor in the 
study. Therefore, it cannot be claimed with certainty that the observed differences between the 
Tox and No-Tox samples were a result of handling the Tox samples in a toxicological 
environment, and not a function of time. While the correlation analyses (Appendix C, Section 
C.3 and Section C.4) showed that the difference in the elapsed time between death and sample 
collection and that between death and DNA extraction, had no influence on the trends of the 
data, the current study did not account for the time difference between the post-collection 
processing of No-Tox samples and that of Tox samples. This can be addressed in further studies 
by introducing a control sample – duplicate No-Tox samples from which DNA will be 







It should be noted, however, that the limitation highlighted above does not nullify the usability 
of the results of this experiment in the intended toxicogenetic analysis. This is because whether 
the observed changes were caused by time or exposure to a toxicological environment, both 
these would still be a factor in real life and the current study was able to show that exposing 
blood samples stored in red-top tubes to a toxicological environment over a period of 16 weeks 
does not affect the usability of the DNA for Sanger sequencing. If, in future studies, leaving 
DNA for longer in postmortem blood samples would be found to be the sole cause of the 
observed differences between the Tox and No-Tox samples, it would mean that exposing blood 
samples to a toxicological environment may not have an effect on the quality, concentration, 
degradation, contamination, and purity of DNA. If, however, handling the samples in a 
toxicology environment could be found to be an important factor, then this study successfully 
demonstrated that blood samples collected and stored in red-top tubes are suitable for use in a 




Postmortem blood specimens collected into different types of blood collection tubes (purple-
top, grey-top, and red-top tubes) and divided into two groups – samples handled in a 
toxicological environment and those that were not – underwent various genetic analyses. The 
red-top tube was shown to be the vial best suited to the storage of blood specimens on which 
Sanger sequencing will subsequently be performed. The higher DNA concentrations observed 
in grey-top tubes did not translate into higher quality electropherograms. The lower purity of 
DNA samples derived from blood handled in a toxicological environment did not impede their 
usability in DNA sequencing. The limitations of the study were found not to negate the findings 
made and the application thereof. Overall, blood samples collected and stored in red-top tubes 
(and not grey-top tubes) over a period of 16 weeks were found to be suitable for use in a genetic 
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CHAPTER 6: APPENDICES 
 
















APPENDIX B.1:  
INFORMATION FORM AND INFORMED CONSENT FORM 
INFORMATION FORM 
 
Study title: Postmortem Toxicogenetics: Determining the suitability of blood samples collected for 
routine toxicological analyses for use in subsequent genetic analyses. 
 
Researcher: Loyiso Vuko 
Supervisor: Ms. Bronwen Davies 
Co-supervisors: Laura Heathfield and Ms. Katrina Auckloo 
 
Introduction to the study 
You are invited to participate in a research study under University of Cape Town’s Division of Forensic 
Medicine and Toxicology, in the Department of Pathology. It will be conducted by Loyiso Vuko, who 
is a researcher in the division, and a candidate for an M.Phil degree in Biomedical Forensic Science.  
 
The purpose of this study is to determine whether blood – a biological sample that is routinely collected 
at autopsy for toxicological analyses (tests that investigate the presence and amount of drugs/chemicals 
in the body of the deceased) – can be used for a genetic analysis following toxicological analysis. This 
form explains what you will be asked to do if you decide to participate in this study. Please read it 




Forensic Pathologists are often faced with cases in which it is not clear from the toxicological analysis 
performed on samples collected from deceased individuals, whether a death was a result of an 
intentional or accidental overdose. A test that could be utilised to answer this uncertainty is one that 
examines if the decedent is not genetically predisposed to experience toxicity from a drug even when 
taken at normal levels. However, before such a test could be performed, it is important to determine 
whether the collection tubes into which blood is usually collected at autopsy can keep the blood in a 
condition that renders it suitable for use in the said genetic test. This is what this study aims to 
investigate, which would, in turn, inform Forensic Pathologists as to whether or not blood collected into 
the aforementioned collection tubes can be used for the specified genetic test. 
 
Procedure 
You will be asked to give permission to allow for blood to be collected at autopsy by the Forensic 
Pathologist assigned the case for your deceased family member. The samples will be collected into 
three different types of collection tubes. Samples collected into the two types of tubes – which are 
routinely used for toxicological analysis – will undergo toxicological analysis, and the samples collected 
into the tube custom-made to preserve DNA will not undergo toxicological analysis. DNA will be 
extracted in all the samples and compared between the different tubes by means of laboratory tests that 







The biological material collected from your deceased family member and the extracted DNA will be 
stored for a period of 20 years at the Division of Forensic Medicine and Toxicology (authorised 
institution) at the University of Cape Town. After this time the samples will be appropriately discarded. 
 
The name and every other personal detail of your family member will not be made known. Each case 
will be given a unique identification code to maintain the anonymity of the deceased. These 
identification codes will be used to trace the collected samples throughout the course of the research. 
The confidentiality of the samples and data will be maintained. 
 
The biological samples will not be used for any research unless the research study is reviewed and 
approved by the University of Cape Town, Faculty of Health Sciences, Human Research Ethics 
Committee. This committee is responsible for protecting the rights and welfare of individuals who 
volunteer for participation in research studies.   
There are several things you need to know before allowing biological samples to be taken from 
your deceased family member: 
1. When research is carried out, it is not the policy of the University of Cape Town to provide 
genetic information about the deceased to the family members.  
2. Participation in this study is voluntary. You are free not to participate or to withdraw at any 
time, for whatever reason, without negative consequences. In such cases, no samples will be 
collected and your choice will not affect the way you will be treated at the Salt River Mortuary. 
3.  If you participate in the study, you can change your mind later and decide that you don’t want 
to participate anymore and you do not want the tissue to be used in this study. Please let us 
know and we will destroy the samples. If the sample has already been analysed at the time you 
change your mind, your results and other data may have already been shared with other 
investigators. In that case, we will not be able to destroy this data. The data will be removed 
from the secured database. That means that no additional researchers can get the data.  
4. You will not receive feedback of possible genetic variations that are found in the DNA of the 
deceased. This study is unlikely to benefit you or your family directly, but it is hoped that it 
will contribute to knowledge about the influence of genes in drug-toxicity in the future. 
5. There will be no cost to you and there will be no compensation for your participation. 
 
 
Making your choice 
Please read each sentence below and think about your choice. After reading each sentence, please tick 
the Yes or No box.  No matter what you decide, it will not negatively affect you or your deceased family 
member in any way. 
 
If you may have any questions or require referral to a grief center or psychological support, please don’t 
hesitate to ask the person taking the consent. If you may have any questions with regards to the rights 






Town Faculty Of Health Science Human Research Ethics Committee, Professor Marc Blockman 
on (021) 406 6496. If you require any further information about this study, please contact Laura 
Heathfield: (0212) 406 6569 or laura.heathfield@uct.ac.za. 
 
If the spouse/partner/major child/parent/guardian/major sibling agrees then the consent form needs to 
be read and informed consent will be taken. Please note that the information and consent forms will 
be translated into the family member’s language of choice.  
 
 
- Thank you for your time - 




I, _______________________________________________________________ (next-of-kin, 
full name), the spouse/partner/major child/parent/guardian/major brother/major sister (circle 
relationship) of the deceased - 
1. Confirm that I have: Yes No 
a) Read and understood contents of this form, been informed about this 
study’s purpose, procedures, possible benefits, and risks, and agree to 
be a part of the research study. 
  
 
2. Give consent and agree that: Yes No 
a) Blood sample(s) can be taken from my deceased family member and 
subjected to laboratory tests at the Division of Forensic Medicine and 
Toxicology  
  
b) The blood samples and extracted DNA may be stored for a period of 
20 years after which it will be appropriately discarded. 
  
c) The stored blood and genetic material may only be used for further 
research which have been reviewed and approved by the University of 
Cape Town, Faculty of Health Sciences Human Research Ethics 
Committee.  
  
d) I may be contacted in the future by someone from the University of 
Cape Town who may ask me to take part in research that may develop 
from the results of the study. 
  
   
3. Further understand that: Yes No 
a) The treatment and management of the biological samples of my 
deceased family member will be in accordance with the guidelines of 
the University Of Cape Town Faculty Of Health Science Human 
Research Ethics Committee. 
  
b) This study is unlikely to benefit me or my family directly.   
c) I can, at any time, withdraw my consent and that I have to notify the 
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I have explained to _________________________________________________(full name) 
who is the spouse/partner/major child/parent/guardian/major brother/major sister of the 
deceased;  the purpose, procedures, possible benefits and discomfort of this research study; and 
how the samples will be collected and stored for use in the study and in possible further research 
by other individuals within the Division of Forensic Medicine and Toxicology at the University 
of Cape Town.  
   
Full name of person obtaining consent  
   
Signature of person obtaining consent   Date      
   
Full name of person authorising consent for collection of samples at autopsy for use in research 
study  
   
Signature of person authorising consent for                                          Date 
collection of samples at autopsy for use in research study 
Thumb print of the next-of-kin of the deceased:                              
   
 
 
Full name of witness      
              










ISIHLOMELO B.2:  
IFOMU YOLWAZI KUNYE NEFOMU YEMVUME ESEKELWE ELWAZINI 
IFOMU YOLWAZI 
 
Isihloko sophando: Postmortem Toxicogenetics: Ukufumanisa ukufaneleka kwegazi elisetyenziswa 
ngokusesikweni kuhlalutyo lwetoxicology ekusetyenzisweni kuvavanyo lwemfuza.  
 
Umphandi: Mnu. Loyiso Vuko 
Umphathi: Nksk. Bronwen Davies 
Usekela-mphathi: Nksk. Laura Heathfield kunye noNksk. Kathrina Auckloo 
 
Intshayelelo yophando 
Uyamenywa ukuba athathe inxaxheba kwisifundo sophando esiphantsi kweCandelo leForensic 
Medicine neToxicology, kwiSebe lePathology, eYunivesithi yaseKapa. Luya kuqhutywa nguLoyiso 
Vuko, ongumphandi kwicandelo, kwaye ongumviwa kwisidanga seM.Phil esifundweni seBiomedical 
Forensic Science. 
 
Injongo yolu phando kukuqinisekisa ukuba igazi – lona elisetyenziswayo ngokwesiqhelo kuvavanyo 
lwetoxicology (uhlalutyo oluyindlela yokuphanda ubukho kunye nesixa seziyobisi emzimbeni womntu) 
– lingasetyenziswa kuhlalutyo lwemfuza (genetics) emva kohlalutyo lwetoxicology olwenziwa kumfi. 
Le fomu icacisa ukuba uza kucelwa ntoni xa uthathe isigqibo sokuba uzathatha inxaxheba kolu phando. 
Nceda uyifunde ngononophelo kwaye uzive ukhululekile ukubuza nayiphi na imibuzo onokuba nayo 
ngaphambili kokuba uthathe isigqibo malunga nokuthatha inxaxheba. 
 
Imvelaphi yophando 
Ogqirha bakwaForensic Pathology badla ngokujongana nemeko apho kungacaciyo kutyando 
olwenziwayo kubantu abangasekhoyo ukuba ukusweleka komfi kubangelwe kukuthatha 
iziyobisi/amachiza ngaphezulu komlinganiselo ngenjongo okanye ngempazamo. Uvavanyo olinokuthi 
lusetyenziswe ukuphendula esisehlo loluphonononga ukuba umfi akanafuzo olumenza atyhefeke 
lichiza naxa elithathe ngokomlinganiselo. Nangona kunjalo, phambi kokuba uvavanyo oluloluhlobo 
lwenziwe, kubalulekile ukuqinisekisa ukuba izikhongozeli ezidla ngokusetyenziswa ukuqokelela igazi 
kolu tyando ziyakwazi ukugcina igazi likwimeko efanelekileyo ukuze lisetyenziswe koluvavanyo 
lwemfuza. Esi sifundo sijolise ekuphandeni lonto, yaye iziphumo ziyakuthi zazise oogqirha 
bakwaForensic Pathology ukuba igazi eliqokelelwe kwezizikhongozeli ezikhankanyiweyo 
lingasetyenziswa koluvavanyo lwemfuza osoluxeliweyo. 
 
Inkqubo yophando 
Uya kucelwa ukuba unike imvume yokuba igazi liqokelelwe xa kusenziwa utyando kwilungu losapho 
lwakho ngugqirha. Eli gazi lizakufakwa kwiintlobo ezintathu ezahlukileyo zezikhongozeli 
zokuqokelela igazi. Kwiintlobo ezimbini zezikhongozeli kuza kufakwa igazi elizakusetyenziswa 
ukuphanda amachiza okanye iziyobisi ezisegazini lomfi kuhlalutyo lwetoxicology. Igazi elifakwe 
kweyesithathu intlobo yesikhongozeli – esisetyenziswa ngokusesikweni ukulondoloza iDNA – 
alizukusetyenziswa koluhlalutyo lwetoxicology. Emveni koko, iDNA iya kuthathwa kuwo onke 
amagazi kwaye ithelekiswe phakathi kwezikhongozeli ezahlukileyo ngokusebenzisa iimvavanyo 





Igazi kunye neDNA ezithathwe kwilungu elingasekhoyo losapho lwakho liya kugcinwa isithuba 
seminyaka angama-20 kwiCandelo leForensic Medicine neToxicology (iziko eligunyazisiweyo), 
eYunivesithi yaseKapa. Emva kwesi sithuba leDNA iya kutshatyalaliswa ngokufanelekileyo. 
 
 
Igama kunye nezinye iinkcukacha zobuqu zelungu losapho lwakho aziyi kwaziswa. Ityala ngalinye liya 
kunikwa isazisi esahlukileyo ukufihla iinkcukacha zomfi. Esi sazisi siya kusetyenziselwa ukulandelela 
igazi lomfi lude lufikele esiphelweni uphando. 
 
 
Igazi elitsaliweyo aliyi kusetyenziselwa naluphi na uphando ngaphandle kophando oluye 
lwaphononongwa ngokutsha lamkelwa yiHuman Research Ethics Committee yaseYunivesithi 
yaseKapa. Le komiti inoxanduva lokukhusela amalungelo kunye nentlalontle yabantu abathatha 
inxaxheba kuphando. 
 
Izinto ekufuneka uzazi phambi kokuba uvume ukuba igazi litsalwe kwilungu elingasekhoyo 
losapho lwakho zezi: 
6. Xa uphando luqhuba, umgaqo siseko weYunivesithi yaseKapa awuvumi ukuba amalungu 
osapho aziswe malunga nemfuza yalowo ungasekhoyo. 
 
7. Ukuthatha inxaxheba kolu phando akusosinyanzeliso. Ukhululekile ukuba wale okanye 
urhoxise isigqibo sakho nangaliphi na ixesha, ngenxa yaso nasiphi na isizathu. Kwiimeko 
ezinjalo, igazi aliyi kutsalwa kwaye ukhetho lwakho aluyi kuchaphazela indlela ophathwa 
ngayo kwimortuary yaseSalt River. 
8. Ukuba uthathe inxaxheba kolu phando, ungaphinde utshintshe ingqondo yakho, urhoxise 
isigqibo sakho. Nceda usazise xa kunjalo ukwenzele sizo kutshabalalisa igazi elitsaliweyo. 
Ukuba igazi sele lisetyenzisiwe ngexesha otshintsha ingqondo ngalo, kungenzeka ukuba 
iziphumo zalo kunye nezinye iinkcukacha sele kwabelwene ngazo nabanye abaphandi. Xa 
kunjalo, asiyi kuba nako ukurhoxisa ezoziphumo. Kodwa ezo nkcukacha ziya kususwa 
kuvimba okhuselekileyo. Oko kuthetha ukuba abekho abanye abaphandi abazakwazi 
ukuzifumana iziphumo zegazi lelungu losapho lwakho. 
9. Awuyi kufumana ngxelo ngenkcukacha zemfuza ezifumaneka kwiDNA yomfi. Olu phando 
alunayo inzuza eqonde wena okanye usapho lwakho ngqo, kodwa sinethemba lokuba iziphumo 
zalo ziya kuba negalelo kulwazi malunga nempembelelo yemfuza ekutyhefekeni. 






Ukwenza ukhetho lwakho 
Nceda ufunde isivakalisi ngasinye apha ngezantsi ulandelise ngokucinga ukhetho lwakho. Emva 
kokufunda isivakalisi ngasinye, nceda uphawule Ewe okanye Hayi kwibhokisi oyinikiweyo. Isigqibo 
sakho asiyi kuchaphazela wena okanye ilungu elingasekhoyo losapho lwakho nangayiphi na indlela. 
 
Ukuba unokuba nayiphi na imibuzo okanye ufuna ukuthunyelwa kwiziko elijongene nabo 
basentlungwini okanye inkxaso ngokwasengqondweni, nceda ungathandabuzi ukubuza umntu othatha 
lemvume. Ukuba unokuba nayiphi na imibuzo malunga namalungelo kunye nentlalontle yalowo uthatha 
inxaxheba kuphando, nceda uqhagamshelane noSihlalo weHuman Research Ethics Committee 
yaseYunivesithi yaseKapa kwiFaculty yeHealth Science, uNjingalwazi Marc Blockman ku (021) 406 
6496. Ukuba ufuna nayiphi na ingcaciso engaphezulu ngesi sifundo, nceda uqhagamshelane noLaura 
Heathfield: (0212) 406 6569 okanye laura.heathfield@uct.ac.za. 
 
Ukuba umlingane/iqabane/umntwana omdala/umzali/umgcini/inkulu yekhaya iyayinikeza imvume, 
ifom yemvume kufuneka ifundwe phambi kokuba kuthatyathwe imvume. Nceda uqaphele ukuba le 
ngcaciso kunye nalemvume ziza kuguqulelwe kulwimi olukhethileyo. 
 
 
- Enkosi ngexesha lakho - 






Mna, _______________________________________________________________ (igama 
elipheleleyo lesalamane), umlingane/iqabane/umntwana omdala/umzali/umgcini/ubhuti 
omdala/ udade omdala womfi – 
 
4. Ndiyaqinisekisa ukuba: Ewe Hayi 
b) Ndikufundile ndakuqonda okubhalwe kule fomu, ndazisiwe 
ngenjongo, iinkqubo, imivuzo, neengozi zoluphando, yaye ndiyavuma 
ukuba yinxalenye yesi sifundo. 
  
 
5. Ndinika imvume kwaye ndiyavuma ukuba: Ewe Hayi 
e) Igazi lingatsalwa kwilungu elingasekhoyo losapho lwam kwaye 
livavanywe elebhu kwiCandelo leForensic Medicine neToxicology. 
  
f) Igazi neDNA ezitsaliweyo zingagcinwa isithuba seminyaka angama-
20 emva koko zizakutshatyalaliswa ngokufanelekileyo. 
  
g) Igazi eligciniweyo neDNA zingasetyenziswa kuphando oluye 
laphononongwa lamkelwa yiHuman Research Ethics Committee 
yaseYunivesithi yaseKapa kuphela. 
  
h) Ndingaqhagamshelwa kwixesha elizayo ligosa laseYunivesithi 
yaseKapa licele ukuba ndithathe inxaxheba kwisifundo esiphuhlisa 
iziphumo zoluphando. 
  
   
6. Ngaphezu koko, ndiyaqonda ukuba: Ewe Hayi 
d) Impatho nolawulo lwegazi lelungu losapho lwam iya kuhambelana 
nezikhokelo zeHuman Research Ethics Committee yaseYunivesithi 
yaseKapa. 
  
e) Olu phando aluyi kuba namvuzo kum okanye usapho lwam ngqo.   
f) Ndingakwazi, nangaliphi na ixesha, ukurhoxisa imvume yam yaye 
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Ndicacisile ku _________________________________________________(igama 
elipheleleyo) ongumlingane/iqabane/umntwana omdala/umzali/umgcini/ubhuti omdala/ udade 
omdala womfi; injongo, iinkqubo, imivuzo nobungozi boluphando; indlela elizathathwa 
ligcinwe ngayo igazi ukuze lisetyenziswe kwesisifundo nakwezinye kwixesha elizayo 
ezizakuqhutywa ngabaphandi abaphantsi kweCandelo leForensic Medicine neToxicology, 




Igama elipheleleyo lomntu uthatha imvume 
   
 
Utyikityo lomntu othatha imvume                  Umhla     
 
   




Utyikityo lomntu ogunyazisa imvume     Umhla 
yokuthathwa kwegazi elizakusetyenziswa kuphando 
 Ushicilelo lukabhontsi wesalamane salowo ungasekhoyo:                              
   
 
 
Igama elipheleleyo lengqina      
 
 
              




ADDENDUM B.3:  
INFORMASIE VORM EN INGELIGTE TOESTEMMING VORM 
INFORMASIE VORM 
 
Studie Titel: Nadoodse Toksiko-genetika: Geskiktheid bepaling van bloed monsters ingesamel tydens 
roetine toksikologiese ontleding vir die gebruik in daaropvolgende genetiese analise.  
 
Navorser: Mnr. Loyiso Vuko 
Studieleier: Me. Bronwen Davies 
Mede-studieleiers: Me. Laura Heathfield en Me. Katrina Auckloo 
 
Inleiding tot die studie 
 
U word genooi om deel te neem aan ŉ navorsingstudie by die Universiteit van Kaapstad, 
Divisie van Forensiese Medisyne en Toksikologie, Departement van Patologie. Die navorsing 
word onderneem deur Loyiso Vuko, ŉ navorser in die divisie en ŉ kandidaat vir ŉ MPhil graad 
in Biomediese Forensiese Wetenskap.  
 
Die doel van hierdie studie is om te bepaal of bloed, ŉ biologiese monster wat normaalweg 
geneem word tydens ŉ nadoodse ondersoek vir toksikologiese ontledings (toetse wat die 
teenwoordigheid en hoeveelheid van sekere dwelms/chemikalieë/terapeutiese middels in die 
liggaam van die oorledene ondersoek) – gebruik kan word vir genetiese analise wat volg op 
die toksikologiese toetse. Hierdie vorm verduidelik wat van u gevra sal word as u besluit om 
deel te neem in die navorsing. Lees asseblief die informasie hieronder aandagtig en bespreek 




Forensiese Patoloë is gereeld betrokke in gevalle waar daar onduidelikheid is aangaande die 
toksikologiese resultate van monsters geneem tydens outopsie, spesifiek die onderskeid tussen 
ŉ opsetlike oordosis of ŉ toevallige/ongeluk oordosis. Een manier wat gebruik kan word om 
hierdie onduidelikheid aan te spreek is om te bepaal of die oorledene geneties ingestel is om 
toksiese vlakke van ŉ middel te ervaar, alhoewel ŉ normale dosis geneem was. Daar moet egter 
eers bepaal word of die versameling buise waarin die bloedmonsters geneem word, geskik is 
vir genetiese toetse. Die voorgenoemde stelling is die vraagstuk vir hierdie navorsing en sal in 




U sal gevra word om toestemming te gee vir die insameling van ŉ bloedmonster tydens 
outopsie van u oorlede familielid. Die Forensiese Patoloog toegeken aan die saak sal die 
bloedmonster neem. Drie verskillende buise sal gebruik word vir die insameling. Twee van 
hierdie buise is roetine toksikologiese buise en sal toksikologiese ontleding ondergaan. Die 
derde tipe buis preserveer DNS en sal nie toksikologiese ontleding ondergaan nie. DNS sal 
onttrek word vanuit al die bloedmonsters en vergelyk word op grond van verskillende tipes 
laboratorium toetse. Hierdie toetse sluit in; spektrofotometrie, kwantitatiewe polimerase 
ketting reaksie en DNS profilering.  
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Die bloedmonster geneem van u familielid én die DNS onttrek uit die monster sal vir 20 jaar 
gestoor word in die Divisie van Forensiese Medisyne en Toksikologie (gemagtigde instansie) 
by die Universiteit van Kaapstad. Na hierdie tydperk sal die monsters op ŉ toepaslike manier 
vernietig word.  
 
Die naam van u familielid, asook enige ander persoonlike inligting, sal op geen manier bekend 
gemaak word nie. Elke geval word ŉ unieke studie kode gegee om anonimiteit te behou. 
Hierdie kode word slegs gebruik om die monsters te spoor tydens die leeftyd van die navorsing. 
Die vertroulikheid van alle monsters en data sal ten alle tye behou word.  
 
Die monsters sal nie vir navorsing gebruik word, tensy die navorsing hersien en goedgekeur 
word deur die Universiteit van Kaapstad, Fakulteit Gesondheidswese, Menslike Navorsing 
Etiek Komitee. Dié komitee is verantwoordelik vir die beskerming van die regte en welsyn van 
individue wat deel neem aan navorsing.  
 
Daar is verskeie aspekte wat u uself moet van verwittig voor u instem dat biologiese 
monsters geneem mag word van u oorlede familielid: 
 
1. Wanneer navorsing onderneem word, is dit nie die beleid van die Universiteit van 
Kaapstad dat enige genetiese informasie teruggee word aan familielede nie.  
 
2. Deelname aan hierdie navorsing is vrywillig. U is gemagtig om te verkies dat u 
familielid nie deel vorm van die studie nie, asook kan u enige tyd verkies om te onttrek 
uit die studie vir enige rede sonder gevolge. In só ŉ geval sal geen monsters geneem 
word nie en u keuse sal onder geen omstandighede affekteer hoe u behandel word by 
‘Salt River Mortuary’ nie.  
 
3. As u nou instem vir deelname in die navorsing maar later besluit om te onttrek moet u 
asseblief die navorser laat weet. In só ŉ geval sal die biologiese materiaal vernietig 
word. As die biologiese monster reeds analise ondergaan het, mag die resultate van die 
analise moontlik al reeds gedeel wees met ander navorsers. Dus sal die data nie ten 
volle verwyder kan word nie. Alhoewel, die data sal verwyder word van die databasis 
sodat geen addisionele navorsers die data sal kan ontleed nie.  
 
4. U sal nie terugvoer ontvang van enige genetiese mutasies gevind in die DNS van u 
familielid nie. Dit is onwaarskynlik dat die studie, u of u familie direk sal bevoordeel. 
Dit word egter beoog dat die navorsing sal bydra tot ons kennis aangaande die invloed 
van gene in dwelm-toksisiteit.  
 
5. Daar is geen koste gebonde aan deelname in die navorsing nie. U sal ook geen 
vergoeding ontvang vir deelname nie.  
 
Om u keuse te maak 
 
Lees asseblief elke stelling hieronder aandagtig voor u antwoord. Na u elke stelling gelees het, 
merk asseblief die ‘Ja’ of ‘Nee’ boksie. Ongeag wat u antwoord is op enige van die stellings, 
dit sal nie u, of u familielid, negatief beïnvloed nie.  
 
As u enige navrae het, of u benodig verwysing na ŉ beradingsentrum of psigologiese 
ondersteuning, moet asseblief nie huiwer om u vraag te rig aan die persoon wat hierdie vorm 
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bespreek nie. As u enige navrae het aangaande die regte en welsyn van individue in navorsing, 
kontak gerus die voorsitter van die Universiteit van Kaapstad, Fakulteit Gesondheidswese, 
Menslike Navorsing Etiek Komitee, Professor Marc Blockman op (021) 406 6496. As u enige 
verdere inligting benodig aangaande die studie onderwerp, kontak gerus vir Laura Heathfield 
op (021) 406 6569 of laura.heathfield@uct.ac.za. 
 
Indien die eggenoot/vennoot/kind/ouer/voog/broer/suster in stem, moet die ingeligte 
toestemmingsvorm gelees en ingevul word. Neem asseblief kennis dat die 
toestemmingsvorm vertaal sal word in die verkose taal van die naasbestaande.  
 
-U word bedank vir u tyd - 






(naasbestaande, volle name), die eggenoot/vennoot/kind/ouer/voog/broer/suster (omsirkel 
verhouding) van die oorledene -  
7. Bevestig dat ek: Ja Nee 
c) Die inhoud van hierdie vorm gelees en verstaan het, dat ek ingelig is 
aangaande die doel van die navorsing, enige prosedures, voordele en 
gevare en ek gee my toestemming vir deelname in die studie. 
  
 
8. Gee toestemming en stem in dat: Ja  Nee 
i) Bloedmonsters van my oorlede familielid mag geneem word en 
onderwerp word aan laboratorium toetse by die Divisie van Forensiese 
Medisyne en Toksikologie. 
  
j) Die bloedmonsters en DNS gestoor mag word vir ŉ tydperk van 20 jaar 
waarna dit toepaslik sal vernietig word. 
  
k) Die gestoorde bloed en genetiese materiaal net vir verdere navorsing 
gebruik mag word indien dié navorsing hersien en goedgekeur word 
deur die Universiteit van Kaapstad, Fakulteit Gesondheidswese, 
Menslike Navorsing Etiek Komitee. 
  
l) Ek mag gekontak word in die toekoms deur die Universiteit van 
Kaapstad wat my mag vra om deel te neem in navorsing wat moontlik 
kan ontwikkel deur die resultate van die huidige navorsing. 
  
   
9. Verstaan verder dat: Ja Nee 
g) Die behandeling en bestuur van die biologiese monsters van my 
oorlede familielid sal geskied in oorstemming met die riglyne van die 
Universiteit van Kaapstad, Fakulteit Gesondheidswese, Menslike 
Navorsing Etiek Komitee. 
  
h) Dit is onwaarskynlik dat die studie my of my familie direk sal 
bevoordeel.  
  
i) Ek mag enige tyd my toestemming onttrek en ek moet die hoof 
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Ek het verduidelik aan ______________________________________________ (volle name), 
die eggenoot/vennoot/kind/ouer/voog/broer/suster van die oorledene; die doel van die 
navorsing, enige prosedures, voordele en gevare; hoe die bloedmonsters geneem en gestoor sal 
word tydens hiérdie navorsing en moontlike toekomstige navorsing deur ander navorsers by 
die Divisie van Forensiese Medisyne en Toksikologie, Universiteit van Kaapstad.  
 
 
   
Volle name (Persoon wat toestemming verkry) 
   
Handtekening (Persoon wat toestemming verkry)   Datum 
   
Volle name (Naasbestaande) 
   
Handtekening (Naasbestaande)                                         Datum 
 
Duim afdruk van naasbestaande:                              
   
 
 
Volle name (Getuie) 
              









APPENDIX C: SUPPLEMENTARY DATA 
C.1. DNA Quantification by spectrophotometry. 
To see if the trends seen for the concentrations obtained by qPCR were reproduced in an 
analytical technique with a different principle, DNA concentrations were also assessed using 
spectrophotometry, where an average concentration of elution 1 and elution 2 was calculated 
for each tube. The distributions and median concentrations for all the sample types are shown 
in Figure S1. 
 
 
Figure S1: DNA concentration assessed by spectrophotometry. Postmortem blood samples (4 mL) were 
collected into three types of blood collection tubes: purple-top (P), grey-top (G), and red-top (R) tubes. The blood 
samples were stored at 4˚C and DNA was isolated within 72 hours of collection from the No-Tox samples. The 
G-Tox and R-Tox tubes were handled in a toxicological environment (at 4˚C) and DNA was extracted 
approximately 16 weeks after blood collection. DNA was extracted using the QiaAmp DNA Investigator’s Kit 
(Qiagen, Hilden, Germany) and NanoDrop 2000 (Thermo Scientific, Massachusetts, USA) was used to quantitate 
the isolated DNA on the day of its extraction. 
 
The concentrations obtained by spectrophotometry were generally higher (average = 32.3 
ng/µL) than those obtained by qPCR (average = 20.0 ng/µL). As was the case with qPCR 
concentrations (Figure 1), the R-No-Tox group produced the highest median concentration of 
43.6 ng/µL. However, contrary to what was seen in qPCR analysis, the R-Tox group produced 
the second highest median concentration of 32.0 ng/µL. This also means that, in the Tox inter-
tube type analysis, the G-Tox group had a lower median concentration (29.1 ng/µL), which 
contradicts the qPCR results (Figure 1). It was also noted that the G-Tox medial concentration 
was similar to that of the grey-top tubes that were not handled in a toxicological environment 
(29.4 ng/µL). The purple-top group had the lowest median concentration of 27.3 ng/µL. 
 
 



















C.2. Assessment of the quality of DNA by Sanger sequencing 
 




II: Reverse orientation 
 
Figure S2: A portion of the DNA sequence of target B. Postmortem blood samples (4 mL) were collected into 
two types of blood collection tubes: grey-top (GT) and red-top (RT) tubes. The blood samples were handled in a 
toxicological environment (at 4˚C) and DNA was isolated approximately 16 weeks after collection using the 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany). The targets of CYP2D6 were amplified by PCR 
using primers designed in-house. The sequences of the (I) forward complement and the (II) reverse complement 
of target B were determined by a Sanger sequencing method that utilised the BigDye Terminator v3.1 Cycle 













II: Reverse orientation 
 
Figure S3: A portion of the DNA sequence of target C. Postmortem blood samples (4 mL) were collected into 
two types of blood collection tubes: grey-top (GT) and red-top (RT) tubes. The blood samples were handled in a 
toxicological environment (at 4˚C) and DNA was isolated approximately 16 weeks after collection using the 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany). The targets of CYP2D6 were amplified by PCR 
using primers designed in-house. The sequences of the (I) forward complement and the (II) reverse complement 
of target C were determined by a Sanger sequencing method that utilised the BigDye Terminator v3.1 Cycle 









Figure S4: A portion of the DNA sequence of target D. Postmortem blood samples (4 mL) were collected into 
two types of blood collection tubes: grey-top (GT) and red-top (RT) tubes. The blood samples were handled in a 
toxicological environment (at 4˚C) and DNA was isolated approximately 16 weeks after collection using the 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany). The targets of CYP2D6 were amplified by PCR 
using primers designed in-house. The sequence of the reverse complement of target D was determined by a Sanger 
























II: Reverse orientation 
 
Figure S5: A portion of the DNA sequence of target E. Postmortem blood samples (4 mL) were collected into 
two types of blood collection tubes: grey-top (GT) and red-top (RT) tubes. The blood samples were handled in a 
toxicological environment (at 4˚C) and DNA was isolated approximately 16 weeks after collection using the 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany). The targets of CYP2D6 were amplified by PCR 
using primers designed in-house. The sequences of the (I) forward complement and the (II) reverse complement 
of target E were determined by a Sanger sequencing method that utilised the BigDye Terminator v3.1 Cycle 








Figure S6: A portion of the DNA sequence of target F. Postmortem blood samples (4 mL) were collected into 
two types of blood collection tubes: grey-top (GT) and red-top (RT) tubes. The blood samples were handled in a 
toxicological environment (at 4˚C) and DNA was isolated approximately 16 weeks after collection using the 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany). The targets of CYP2D6 were amplified by PCR 
using primers designed in-house. The sequence of the forward complement of target F was determined by a Sanger 








Figure S7: A portion of the DNA sequence of target G. Postmortem blood samples (4 mL) were collected into 
two types of blood collection tubes: grey-top (GT) and red-top (RT) tubes. The blood samples were handled in a 
toxicological environment (at 4˚C) and DNA was isolated approximately 16 weeks after collection using the 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany). The targets of CYP2D6 were amplified by PCR 
using primers designed in-house. The sequence of the forward complement of target G was determined by a 













Figure S8: A portion of the DNA sequence of target H. Postmortem blood samples (4 mL) were collected into 
two types of blood collection tubes: grey-top (GT) and red-top (RT) tubes. The blood samples were handled in a 
toxicological environment (at 4˚C) and DNA was isolated approximately 16 weeks after collection using the 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany). The targets of CYP2D6 were amplified by PCR 
using primers designed in-house. The sequence of the reverse complement of target H was determined by a Sanger 


















I: Forward orientation 
 
 
II: Reverse orientation 
 
Figure S9: A portion of the DNA sequence of target I. Postmortem blood samples (4 mL) were collected into 
two types of blood collection tubes: grey-top (GT) and red-top (RT) tubes. The blood samples were handled in a 
toxicological environment (at 4˚C) and DNA was isolated approximately 16 weeks after collection using the 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany). The targets of CYP2D6 were amplified by PCR 
using primers designed in-house. The sequences of the (I) forward complement and the (II) reverse complement 
of target I were determined by a Sanger sequencing method that utilised the BigDye Terminator v3.1 Cycle 












C.3. Correlation test: period between death and the collection of blood samples 
 
I. Concentration (obtained by qPCR) 
  
 
Figure S10: Correlation between DNA concentration (assessed by qPCR) and time (the period between 
death and the collection of blood samples). Postmortem blood samples (4 mL) were collected into two types of 
blood collection tubes: (A) grey-top and (B) red-top tubes. The blood samples were stored at 4˚C and DNA was 
isolated within 72 hours of collection from the No-Tox samples. The G-Tox and R-Tox tubes were handled in a 
toxicological environment (at 4˚C) and DNA was extracted approximately 16 weeks after blood collection. The 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) was used for DNA extraction. The DNA samples 
were stored at 4˚C until the Quantifiler™ Trio DNA Quantification Kit (Applied Biosystems, California, USA) 

































































Figure S11: Correlation between DNA concentration (assessed by spectrophotometry) and time (the period 
between death and the collection of blood samples). Postmortem blood samples (4 mL) were collected into two 
types of blood collection tubes: (A) grey-top and (B) red-top tubes. The blood samples were stored at 4˚C and 
DNA was isolated within 72 hours of collection from the No-Tox samples. The G-Tox and R-Tox tubes were 
handled in a toxicological environment (at 4˚C) and DNA was extracted approximately 16 weeks after blood 
collection. DNA was extracted using the QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) and 



































































Figure S12: Correlation between degradation indices of isolated human DNA and time (the period between 
death and the collection of blood samples). Postmortem blood samples (4 mL) were collected into two types of 
blood collection tubes: (A) grey-top and (B) red-top tubes. The blood samples were stored at 4˚C and DNA was 
isolated within 72 hours of collection from the No-Tox samples. The G-Tox and R-Tox tubes were handled in a 
toxicological environment (at 4˚C) and DNA was extracted approximately 16 weeks after blood collection. The 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) was used for DNA extraction. The DNA samples 
were stored at 4˚C until the Quantifiler™ Trio DNA Quantification Kit (Applied Biosystems, California, USA) 
was used to determine the degradation indices of the endogenous DNA on a 7500 Real-Time PCR System 























































Figure S13: Correlation between absorbance ratio 260/280 and time (the period between death and the 
collection of blood samples). Postmortem blood samples (4 mL) were collected into two types of blood collection 
tubes: (A) grey-top and (B) red-top tubes. The blood samples were stored at 4˚C and DNA was isolated within 72 
hours of collection from the No-Tox samples. The G-Tox and R-Tox tubes were handled in a toxicological 
environment (at 4˚C) and DNA was extracted approximately 16 weeks after blood collection. DNA was extracted 
using the QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) and NanoDrop 2000 (Thermo Scientific, 













































Figure S14: Correlation between absorbance ratio 260/230 and time (the period between death and the 
collection of blood samples). Postmortem blood samples (4 mL) were collected into two types of blood collection 
tubes: (A) grey-top and (B) red-top tubes. The blood samples were stored at 4˚C and DNA was isolated within 72 
hours of collection from the No-Tox samples. The G-Tox and R-Tox tubes were handled in a toxicological 
environment (at 4˚C) and DNA was extracted approximately 16 weeks after blood collection. DNA was extracted 
using the QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) and NanoDrop 2000 (Thermo Scientific, 










































C.4. Correlation test: period between death and the extraction of DNA 
 
I. Concentration (obtained by qPCR) 
 
 
Figure 15: Correlation between DNA concentration (assessed by qPCR) and time (the period between death 
and the extraction of DNA). Postmortem blood samples (4 mL) were collected into two types of blood collection 
tubes: (A) grey-top and (B) red-top tubes. The blood samples were stored at 4˚C and DNA was isolated within 72 
hours of collection from the No-Tox samples. The G-Tox and R-Tox tubes were handled in a toxicological 
environment (at 4˚C) and DNA was extracted approximately 16 weeks after blood collection. The QiaAmp DNA 
Investigator’s Kit (Qiagen, Hilden, Germany) was used for DNA extraction. The DNA samples were stored at 
4˚C until the Quantifiler™ Trio DNA Quantification Kit (Applied Biosystems, California, USA) was used to 


































































Figure S16: Correlation between DNA concentration (assessed by spectrophotometry) and time (the period 
between death and the extraction of DNA). Postmortem blood samples (4 mL) were collected into two types of 
blood collection tubes: (A) grey-top and (B) red-top tubes. The blood samples were stored at 4˚C and DNA was 
isolated within 72 hours of collection from the No-Tox samples. The G-Tox and R-Tox tubes were handled in a 
toxicological environment (at 4˚C) and DNA was extracted approximately 16 weeks after blood collection. DNA 
was extracted using the QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) and NanoDrop 2000 


































































Figure 17: Correlation between degradation indices of isolated human DNA and time (the period between 
death and the extraction of DNA). Postmortem blood samples (4 mL) were collected into two types of blood 
collection tubes: (A) grey-top and (B) red-top tubes. The blood samples were stored at 4˚C and DNA was isolated 
within 72 hours of collection from the No-Tox samples. The G-Tox and R-Tox tubes were handled in a 
toxicological environment (at 4˚C) and DNA was extracted approximately 16 weeks after blood collection. The 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) was used for DNA extraction. The DNA samples 
were stored at 4˚C until the Quantifiler™ Trio DNA Quantification Kit (Applied Biosystems, California, USA) 
was used to determine the degradation indices of the endogenous DNA on a 7500 Real-Time PCR System 
























































Figure 18: Correlation between absorbance ratio 260/280 and time (the period between death and the 
extraction of DNA). Postmortem blood samples (4 mL) were collected into two types of blood collection tubes: 
(A) grey-top and (B) red-top tubes. The blood samples were stored at 4˚C and DNA was isolated within 72 hours 
of collection from the No-Tox samples. The G-Tox and R-Tox tubes were handled in a toxicological environment 
(at 4˚C) and DNA was extracted approximately 16 weeks after blood collection. DNA was extracted using the 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) and NanoDrop 2000 (Thermo Scientific, 











































Figure 19: Correlation between absorbance ratio 260/230 and time (the period between death and the 
extraction of DNA). Postmortem blood samples (4 mL) were collected into two types of blood collection tubes: 
(A) grey-top and (B) red-top tubes. The blood samples were stored at 4˚C and DNA was isolated within 72 hours 
of collection from the No-Tox samples. The G-Tox and R-Tox tubes were handled in a toxicological environment 
(at 4˚C) and DNA was extracted approximately 16 weeks after blood collection. DNA was extracted using the 
QiaAmp DNA Investigator’s Kit (Qiagen, Hilden, Germany) and NanoDrop 2000 (Thermo Scientific, 














































Femoral blood specimens were collected from 30 cases of deceased individuals examined at 
Salt River Mortuary. Blood was drawn from the femoral vein of the deceased and transferred 
into one 4 mL purple-top tube, two 4 mL grey-top tubes, and into two 10 mL red-top tubes. 
The volume of blood that was aliquoted into each of the five tubes was 4 mL. All the blood 
specimens were immediately transported to the University of Cape Town’s Molecular 
Forensics’ laboratory. The samples were stored at 4˚C and DNA was extracted within 72 hours 
of sample collection from all the samples that would not undergo toxicological analysis, 
identified as the “No-tox” samples: one grey-top tube (G-No-tox), one red-top tube (R-No-
tox), and the purple-top tube (P-No-tox). The remaining grey-top tube and red-top tube (called 
G-Tox and R-Tox, respectively) remained stored at 4˚C at UCT’s Forensic Toxicology Unit 
laboratory until downstream toxicological analysis was performed. These samples were, 




In respect of DNA concentration, degradation index, and purity (A260/280 and A260/230), the 
objectives were: 
(i) To determine if a difference exists between the purple-top tubes and the grey-top 
tubes that have not undergone a toxicological analysis. (P-No-Tox vs G-No-Tox) 
(ii) To determine if a difference exists between the purple-top tubes and the red-top 
tubes that have not undergone a toxicological analysis. (P-No-Tox vs R-No-Tox) 
(iii) To determine if a difference exists between the grey-top tubes and the red-top tubes 
that have not undergone a toxicological analysis. (G-No-Tox vs R-No-Tox) 
(iv) To determine if a difference exists between the grey-top tubes and the red-top tubes 
that have undergone a toxicological analysis. (G-Tox vs R-Tox) 
(v) To determine if a difference exists between the grey-top tubes that have undergone 
toxicological analysis and the grey-top tubes that have not undergone a 
toxicological analysis. (G-No-Tox vs G-Tox) 
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(vi) To determine if a difference exists between the red-top tubes that have undergone 
toxicological analysis and the red-top tubes that have not undergone a toxicological 
analysis. (R-No-Tox vs R-Tox) 
 
3. Exploratory analysis 
 
The samples are dependent; therefore, a matched analysis is appropriate. 
 
3.1. Assessment of normal distribution (Shapiro Wilk test) 
 
Overall, the data is not normally distributed (the p-values for the groups compared are provided 
in the log output below). 
 
3.2. Assessment of normal distribution of difference (Shapiro Wilk Test) 
None of the differences were found to be normally distributed (the p-values for the differences 
are provided in the log output below). 
 
4. Hypothesis testing 
 
The differences are not normally distributed; therefore, the data was analysed using a non-

















5. Log output 
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